Cytotoxic agents comprising new maytansinoids

ABSTRACT

New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the α-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

This application is a continuation of pending U.S. application Ser. No.11/778,451 (Confirmation No. 1451) filed Jul. 16, 2007, which is adivisional of pending U.S. application Ser. No. 10/849,136 (ConfirmationNo. 8145) filed May 20, 2004 (U.S. Pat. No. 7,276,497, issued Oct. 2,2007), which claims benefit of Provisional Application No. 60/471,739,filed May 20, 2003, and Provisional Application No. 60/493,457, filedAug. 8, 2003, the disclosure of each of which is incorporated herein byreference in its entirety.

FIELD OF THE INVENTION

The present invention relates to a method for preparing improvedcytotoxic conjugates comprising maytansinoids and cell-binding agents.These conjugates have therapeutic use as they are delivered to aspecific cell population in a targeted fashion. The present inventionalso relates to a method for preparing maytansinoids having a thiolmoiety, which may be used in the preparation of cytotoxic conjugates.The present invention further relates to novel maytansinoids, and tonovel intermediates in the synthesis of the novel maytansinoids.

BACKGROUND OF THE INVENTION

Many reports have appeared on the attempted specific targeting of tumorcells with monoclonal antibody-drug conjugates (Sela et al. inImmunoconjugates 189-216 (C. Vogel, ed. 1987); Ghose et al, in TargetedDrugs 1-22 (E. Goldberg, ed. 1983); Diener et al, in Antibody MediatedDelivery Systems 1-23 (J. Rodwell, ed. 1988); Pietersz et al, inAntibody Mediated Delivery Systems 25-53 (J. Rodwell, ed. 1988); Bumolet al, in Antibody Mediated Delivery Systems 55-79 (J. Rodwell, ed.1988). Cytotoxic drugs such as methotrexate, daunorubicin, doxorubicin,vincristine, vinblastine, melphalan, mitomycin C, and chlorambucil havebeen conjugated to a variety of murine monoclonal antibodies. In somecases, the drug molecules were linked to the antibody molecules throughan intermediary carrier molecule such as serum albumin (Garnett et al.Cancer Res. 46:2407-2412 (1986); Ohkawa et al. Cancer Immumol.Immunother. 23:81-86 (1986); Endo et al. Cancer Res. 47:1076-1080(1980)), dextran (Hurwitz et al. Appl. Biochem. 2:25-35 (1980); Manabiet al. Biochem. Pharmacol. 34:289-291 (1985); Dillman et al. Cancer Res.46:4886-4891 (1986); Shoval et al. Proc. Natl. Acad. Sci. 85: 8276-8280(1988)), or polyglutamic acid (Tsukada et al. J. Natl. Canc. Inst.73:721-729 (1984); Kato et al. J. Med. Chem. 27:1602-1607 (1984);Tsukada et al. Br. J. Cancer 52:111-116 (1985)).

A wide array of linker technologies has been employed for thepreparation of such immunoconjugates, and both cleavable andnon-cleavable linkers have been investigated. In most cases, the fullcytotoxic potential of the drugs could only be observed, however, if thedrug molecules could be released from the conjugates in unmodified format the target site.

One of the cleavable linkers that has been employed for the preparationof antibody-drug conjugates is an acid-labile linker based oncis-aconitic acid that takes advantage of the acidic environment ofdifferent intracellular compartments such as the endosomes encounteredduring receptor mediated endocytosis and the lysosomes. Shen and Ryserintroduced this method for the preparation of conjugates of daunorubicinwith macromolecular carriers (Biochem. Biophys. Res. Commun.102:1048-1054 (1981)). Yang and Reisfeld used the same technique toconjugate daunorubicin to an anti-melanoma antibody (J. Natl. Canc.Inst. 80:1154-1159 (1988)). Recently, Dillman et al. also used anacid-labile linker in a similar fashion to prepare conjugates ofdaunorubicin with an anti-T cell antibody (Cancer Res. 48:6097-6102(1988)).

An alternative approach, explored by Trouet et al. involved linkingdaunorubicin to an antibody via a peptide spacer arm (Proc. Natl. Acad.Sci. 79:626-629 (1982)). This was done under the premise that free drugcould be released from such a conjugate by the action of lysosomalpeptidases.

In vitro cytotoxicity tests, however, have revealed that antibody-drugconjugates rarely achieved the same cytotoxic potency as the freeunconjugated drugs. This suggested that mechanisms by which drugmolecules are released from the antibodies are very inefficient. In thearea of immunotoxins, conjugates formed via disulfide bridges betweenmonoclonal antibodies and catalytically active protein toxins were shownto be more cytotoxic than conjugates containing other linkers. See,Lambert et al. J. Biol. Chem. 260:12035-12041 (1985); Lambert et al. inImmunotoxins 175-209 (A. Frankel, ed. 1988); Ghetie et al. Cancer Res.48:2610-2617 (1988). This was attributed to the high intracellularconcentration of glutathione contributing to the efficient cleavage ofthe disulfide bond between an antibody molecule and a toxin. Despitethis, there are only a few reported examples of the use of disulfidebridges for the preparation of conjugates between drugs andmacromolecules. Shen et al. described the conversion of methotrexateinto a mercaptoethylamide derivative followed by conjugation withpoly-D-lysine via a disulfide bond (J. Biol. Chem. 260:10905-10908(1985)). In addition, a few reports described the preparation ofconjugates of the trisulfide-containing toxic drug calicheamicin withantibodies (Hinman et al, 53 Cancer Res. 3336-3342 (1993), Hamann etal., Bioconjugate Chem., 13, 40-46 (2002), Hamann et al., BioconjugateChem., 13, 47-58 (2002)).

One reason for the lack of disulfide linked antibody-drug conjugates isthe unavailability of cytotoxic drugs that bear a sulfur atom containingmoiety that can be readily used to link the drug to an antibody via adisulfide bridge. Furthermore, chemical modification of existing drugsis difficult without diminishing their cytotoxic potential.

Maytansinoids are highly cytotoxic drugs. Maytansine was first isolatedby Kupchan et al. from the east African shrub Maytenus serrata and shownto be 100 to 1000 fold more cytotoxic than conventional cancerchemotherapeutic agents like methotrexate, daunorubicin, and vincristine(U.S. Pat. No. 3,896,111). Subsequently, it was discovered that somemicrobes also produce maytansinoids, such as maytansinol and C-3 estersof maytansinol (U.S. Pat. No. 4,151,042). Synthetic C-3 esters ofmaytansinol and analogues of maytansinol have also been reported(Kupchan et al. J. Med. Chem. 21:31-37 (1978); Higashide et al. Nature270:721-722 (1977); Kawai et al. Chem. Pharm. Bull. 32:3441-3451(1984)). Examples of analogues of maytansinol from which C-3 esters havebeen prepared include maytansinol with modifications on the aromaticring (e.g. dechloro) or at the C-9, C-14 (e.g. hydroxylated methylgroup), C-15, C-18, C-20 and C-4,5.

The naturally occurring and synthetic C-3 esters of maytansinol can beclassified into two groups:

(a) C-3 esters with simple carboxylic acids (U.S. Pat. Nos. 4,248,870;4,265,814; 4,308,268; 4,308,269; 4,309,428; 4,317,821; 4,322,348; and4,331,598), and

(b) C-3 esters with derivatives of N-methyl-L-alanine (U.S. Pat. Nos.4,137,230; 4,260,608; 5,208,020; and Chem. Pharm. Bull. 12:3441 (1984)).

Esters of group (b) were found to be much more cytotoxic than esters ofgroup (a).

Maytansine is a mitotic inhibitor. Treatment of L1210 cells in vivo withmaytansine has been reported to result in 67% of the cells accumulatingin mitosis. Untreated control cells were reported to demonstrate amitotic index ranging from between 3.2 to 5.8% (Sieber et al. 43Comparative Leukemia Research 1975, Bibl. Haemat. 495-500 (1976)).Experiments with sea urchin eggs and clam eggs have suggested thatmaytansine inhibits mitosis by interfering with the formation ofmicrotubules through the inhibition of the polymerization of themicrotubule protein, tubulin (Remillard et al. Science 189:1002-1005(1975)).

In vitro, P388, L1210, and LY5178 murine leukemic cell suspensions havebeen found to be inhibited by maytansine at doses of 10⁻³ to 10⁻¹ μg/μlwith the P388 line being the most sensitive. Maytansine has also beenshown to be an active inhibitor of in vitro growth of humannasopharyngeal carcinoma cells, and the human acute lymphoblasticleukemia line CEM was reported inhibited by concentrations as low as10⁻⁷ μg/ml (Wolpert-DeFillippes et al. Biochem. Pharmacol. 24:1735-1738(1975)).

In vivo, maytansine has also been shown to be active. Tumor growth inthe P388 lymphocytic leukemia system was shown to be inhibited over a50- to 100-fold dosage range, which suggested a high therapeutic index;also significant inhibitory activity could be demonstrated with theL1210 mouse leukemia system, the human Lewis lung carcinoma system andthe human B-16 melanocarcinoma system (Kupchan, Ped. Proc. 33:2288-2295(1974)). Maytansinoids used in conjugates with cell-binding agents aredescribed in U.S. Pat. Nos. 5,208,020 and 5,416,064 and in Chari et al.,Cancer Res., 52: 127-131 (1992) and Liu et al., Proc. Natl. Acad. Sci.,93: 8618-8623 (1996). In these conjugates, the cell-binding agent islinked via disulfide bonds to the maytansinoid DM1[N^(2′)-deacetyl-N-^(2′)(3-mercapto-1-oxopropyl)-maytansine, 1, CASNumber: 139504-50-0, FIG. 1]

In the above patents, the maytansinoid drugs bearing acylatedN-methyl-L-alanine side chains are of the formula 2a,b:

In formula 2a, l represents an integer from 1 to 10. Thus maytansinoidsof the formula 2a have the sulfur atom connected to an unsubstitutedmethylene group (—CH₂—S—). It is said that a sulfhydryl group in such amaytansinoid compound or a disulfide group in a disulfide-linkedcell-binding agent-maytansinoid conjugate with such a maytansinoid is“non-hindered,” since there are no bulky substituents on the α-carbonnext to the sulfhydryl or disulfide group, which cause steric hindrance.In formula 2b, m represents 0, 1, 2 or 3. Therefore, maytansinoids ofthe formula 2b also have the sulfur atom connected to an unsubstitutedmethylene group, except in the case where m=0, and R₂═CH₃ or CH₂CH₃. Ifm=0, then the maytansinoid bears one substituent on the carbon bearingthe thiol functionality or a disulfide functionality after conjugationto a cell-binding agent via a disulfide bond. However, because in thiscase the sulfur atom is in the β position relative to a carbonyl group,these maytansinoids and conjugates of such maytansinoids withcell-binding agents via a disulfide bond were found to be unstable dueto their propensity to undergo β-elimination.

SUMMARY OF THE INVENTION

The present invention is based on the unexpected finding that thelinkage of maytansinoids, bearing a sterically hindered thiol group(possessing one or two substituents on the α-carbon bearing the thiolfunctionality), to cell-binding agents gives conjugates that have vastlyimproved anti-tumor activity in vivo as compared to conjugates preparedwith the previously described maytansinoids that did not possess asubstituent on the α-carbon atom bearing the disulfide bond. Anotherunexpected finding was that improved biological activity is obtainedwhen the steric hindrance is optimally on the maytansinoid side of thedisulfide bond in the conjugates. In addition, the acyl group of theacylated amino acid side chain of the maytansinoid bearing thesulfhydryl group has to possess a linear chain length of at least threecarbon atoms between the carbonyl group of the amide and the sulfuratom.

These findings show that disulfide-linked cell-bindingagent-maytansinoid conjugates can be constructed such that substitutionson the two a-carbon atoms bearing the disulfide bond can lead to varyingdegrees of steric hindrance on either side of the disulfide bond.

Accordingly, the present invention describes the synthesis of new,sterically hindered thiol and disulfide-containing maytansinoids, whichbear one or two alkyl substituents on the α-carbon atom bearing thesulfur atom. In addition, the acyl group of the acylated amino acid sidechain possesses a linear chain length of at least three carbon atomsbetween the carbonyl group of the amide and the sulfur atom.

The preparation and biological evaluation of cell-binding agentconjugates of these new maytansinoids is also described.

In one embodiment of the invention, new thiol and disulfide-containingmaytansinoids bearing a mono or di-alkyl substitution on the carbon atombearing the sulfur atom are described.

In a second embodiment, the present invention discloses methods for thesynthesis of these new maytansinoids.

In a third embodiment, methods for the linkage of these newmaytansinoids to cell-binding agents are described. These conjugates areuseful as therapeutic agents, which are delivered specifically to targetcells and are cytotoxic. These conjugates display vastly improvedtherapeutic efficacy in animal tumor models compared to the previouslydescribed agents.

More specifically, the present invention provides:

A maytansinoid having, at C-3, C-14 hydroxymethyl, C-15 hydroxy, or C-20desmethyl, an acylated amino acid side chain with an acyl group bearinga hindered sulfhydryl group, wherein the carbon atom of the acyl groupbearing the thiol functionality has one or two substituents, saidsubstituents being CH₃, C₂H₅, linear or branched alkyl or alkenyl havingfrom 1 to 10 carbon atoms, cyclic alkyl or alkenyl having from 3 to 10carbon atoms, phenyl, substituted phenyl, or heterocyclic aromatic orheterocyclic radical, and in addition one of the substituents can be H,and wherein the acyl group has a linear chain length of at least threecarbon atoms between the carbonyl functionality and the sulfur atom;

A compound represented by formula 4′:

wherein:

Y′ represents(CR₇R₈)_(l)(CR₉═CR₁₀)_(p)(C≡C)_(q)A_(o)(CR₅R₆)_(m)D_(u)(CR₁₁═CR₁₂)_(r)(C≡C)_(s)B_(t)(CR₃R₄)_(n)CR₁R₂SZ,wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

A, B, D are cycloalkyl or cycloalkenyl having 3-10 carbon atoms, simpleor substituted aryl or heterocyclic aromatic or heterocyclic radical;

R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, and R₁₂ are each independently H,CH₃, C₂H₅, linear alkyl or alkenyl having from 1 to 10 carbon atoms,branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms,phenyl, substituted phenyl or heterocyclic aromatic or heterocyclicradical;

l, m, n, o, p, q, r, s, t and u are each independently 0 or an integerof from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s, tand u are not zero at any one time.

Z is H, SR or —COR, wherein R is linear alkyl or alkenyl having from 1to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to10 carbon atoms, or simple or substituted aryl or heterocyclic aromaticor heterocyclic radical.

A compound represented by formula 4′, wherein R₁ is H, R₂ is methyl andZ is H.

A compound represented by formula 4′, wherein R₁ and R₂ are methyl and Zis H.

A compound represented by formula 4′, wherein R₁ is H, R₂ is methyl, andZ is —SCH₃.

A compound represented by formula 4′, wherein R₁ and R₂ are methyl, andZ is —SCH₃.

A compound represented by formula (I-L), (I-D), or (I-D,L):

wherein:Y represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl, orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl, or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0;

Z is H, SR or —COR wherein R is linear or branched alkyl or alkenylhaving from 1 to 10 carbon atoms, cyclic alkyl or alkenyl having from 3to 10 carbon atoms, or simple or substituted aryl or heterocyclicaromatic or heterocyclic radical; and

May represents a maytansinoid which bears the side chain at C-3, C-14hydroxymethyl, C-15 hydroxy or C-20 desmethyl;

The above-described compound, wherein R₁ is H, R₂ is methyl, R₅, R₆, R₇,and R₈ are each H, l and m are each 1, n is 0, and Z is H;

The above-described compound, wherein R₁ and R₂ are methyl, R₅, R₆, R₇,R₈ are each H, l and m are 1, n is 0, and Z is H;

The above-described compound, wherein R₁ is H, R₂ is methyl, R₅, R₆, R₇,and R₈ are each H, l and m are each 1, n is 0, and Z is —SCH₃;

The above-described compound, wherein R₁ and R₂ are methyl, R₅, R₆, R₇,R₈ are each H, l and m are 1, n is 0, and Z is —SCH₃;

A compound represented by formula 4:

wherein:Y represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl, or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0; and

Z is H, SR or —COR, wherein R is linear alkyl or alkenyl having from 1to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to10 carbon atoms, or simple or substituted aryl or heterocyclic aromaticor heterocyclic radical;

The compound of formula 4, wherein R1 is H, R2 is methyl, R5, R6, R7,and R8 are each H; l and m are each 1; n is 0; and Z is H;

The compound of formula 4, wherein R₁ and R₂ are methyl; R₅, R₆, R₇, R₈are each H, l and m are 1; n is 0; and Z is H;

The compound of formula 4, wherein R₁ is H, R₂ is methyl, R₅, R₆, R₇,and R₈ are each H, l and m are each 1, n is 0, and Z is —SCH₃;

The compound of formula 4, wherein R₁ and R₂ are methyl, R₅, R₆, R₇, R₈are each H, l and m are 1, n is 0, and Z is —SCH₃;

A maytansinoid-cell-binding agent conjugate comprising at least onemaytansinoid linked to the cell-binding agent, wherein the maytansinoidis any of the above-described compounds;

Any of the above-described maytansinoid-cell-binding agent conjugates,wherein the cell-binding agent comprises at least one binding site of anantibody, preferably humanized or resurfaced MY9, humanized orresurfaced anti-B4, or humanized or resurfaced C242;

A pharmaceutical composition comprising an effective amount of any ofthe above-described maytansinoid-cell-binding agent conjugates, apharmaceutically acceptable salt or solvate thereof, and apharmaceutically acceptable carrier, diluent or excipient;

A method of esterification of a maytansinoid at C-3, C-14 hydroxymethyl,C-15 hydroxy, or C-20 desmethyl, with an acylated amino acid side chainwhere the acyl group bears a protected sulfhydryl functionality, whereinthe carbon atom of the acyl group bearing the protected thiolfunctionality has one or two substituents, said substituents being CH₃,C₂H₅, linear alkyl or alkenyl having from 1 to 10 carbon atoms, branchedor cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl,substituted phenyl or heterocyclic aromatic or heterocyclic radical, andin addition one of the substituents can be H, and wherein the acyl grouphas a linear chain length of at least three carbon atoms between thecarbonyl functionality and the sulfur atom, said method comprisingreacting a maytansinoid at C-3, C-14 hydroxymethyl, C-15 hydroxy, orC-20 desmethyl, with the acylated amino acid where the acyl group bearsa protected sulfhydryl group;

A method of esterification of a maytansinoid to produce a maytansinoidester represented by formula (IV-L), (IV-D), or (IV-D,L):

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearcyclic alkyl or alkenyl having from 1 to 10 carbon atoms, branched orcyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl,substituted phenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0;

Z₂ is SR or COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical; and

May is a maytansinoid; said method comprising reacting said May at C-3,C-14 hydroxymethyl, C-15 hydroxy, or C-20 desmethyl, with a compound offormula (III-L), (III-D), or (III-D,L):

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linear orbranched alkyl or alkenyl having from 1 to 10 carbon atoms, cyclic alkylor alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenylor heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0; and

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical;

The above-described method, wherein R₁ is H, R₂ is methyl, R₅, R₆, R₇and R₈ are each H; l and m are each 1; and n is 0;

The above-described method, wherein the compound of formula (III) isrepresented by formula (III-L);

The above-described method, wherein the compound of formula (III-L) iscompound 15a(S,S), 15b(S,R) or a mixture of 15a(S,S) and 15b(S,R);

The above-described method, wherein the compound of formula (III-D) iscompound 15(R,S), 15(R,R), or a mixture of 15(R,S) and 15(R,R);

The above-described method, wherein the compound of formula (III-D,L) isracemic N-methylalanine acylated with a carboxylic group bearing aprotected thiol functionality, in which the carbon center bearing thesulfur atom is either racemic or of the R or S chirality to givecompounds of the structure of 15;

The above-described method, wherein the mixture of 15a(S,S) and 15b(S,R)is made by a process comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with N-methyl-L-alanine to give said mixture ofcompounds 15a(S,S) and 15b(S,R);

The above-described method, wherein compound 15a(S,S) is made by amethod comprising:

(1) converting (R)-1,3-butanediol into (S)-4-(methydithio)pentanoic acid19;

(2) converting compound 19 into its N-hydroxysuccinimide ester (20); and

(3) reacting compound 20 with N-methyl-L-alanine to give said compound15a(S,S).

The above-described method, wherein compound 15b(S,R) is made by amethod comprising:

(1) converting (S)-1,3-butanediol into (R)-4-(methydithio)pentanoic acid24;

(2) converting compound 24 into its N-hydroxysuccinimide ester (25); and

(3) reacting compound 25 with N-methyl-L-alanine to give said compound15b(S,R).

The above described method, wherein the mixture of compounds 15(R,S) and15(R,R) is made by a process comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14,

(3) reacting compound 14 with N-methyl-D-alanine to give said mixture ofcompounds 15(R,S) and 15(R,R).

The above-described method, wherein racemic N-methylalanine acylatedwith a carboxylic group bearing a protected thiol functionality, inwhich the carbon center bearing the sulfur atom is either racemic or ofthe R or S chirality to give compounds of the structure of 15 is made bya process comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with racemic N-methylalanine to give theracemic N-methylalanine acylated with a carboxylic group bearing aprotected thiol functionality, in which the carbon center bearing thesulfur atom is either racemic or of the R or S chirality to givecompounds of the structure 15.

The above-described method, wherein R₁ and R₂ are methyl; R₅, R₆, R₇ andR₈ are each H; l and m are each 1; and n is 0;

The above-described method, wherein the compound of formula (III-L) iscompound 10(S) containing N-methyl-L-alanine;

The above-described method, wherein the compound of formula (III-D) iscompound 10(R) containing N-methyl-D-alanine;

The above-described method, wherein the compound of formula (III-D,L) iscompound 10(S,R) containing racemic N-methylalanine;

The above-described method, wherein the compound 10 containingN-methyl-L-alanine, N-methyl-D-alanine or racemic N-methylalanine ismade by a process comprising:

(1) reacting isobutylene sulfide (5) with the anion of acetonitrile togive compound 6;

(2) hydrolyzing compound 6 to give 4-mercapto-4-methylpentanoic acid(7);

(3) converting compound 7 into disulfide 8 by reaction with methylmethanethiolsulfonate;

(4) converting compound 8 into its N-hydroxysuccinimide ester 9; and

(5) reacting compound 9 with N-methyl-L-alanine, N-methyl-D-alanine, orracemic N-methylalanine to give said compound 10 containingN-methyl-L-alanine, N-methyl-D-alanine, or racemic N-methylalanine;

A method of making a maytansinoid by the method of any one of theabove-described methods, separating diastereomers, if present, andpurifying the maytansinoid by HPLC on cyano-bonded silica;

A method of making a maytansinoid-cell-binding agent conjugatecomprising making a purified maytansinoid by any of the above-describedmethods, and reacting the purified maytansinoid with a cell-bindingagent comprising a reactive dithio group or a sulfhydryl group.

The above-described method of making a maytansinoid-cell-binding agentconjugate, wherein the reactive dithio group is a dithiopyridyl group ora substituted dithiopyridyl group;

A method of making a maytansinoid-cell-binding agent conjugatecomprising making a purified maytansinoid by any of the above-describedmethods, and reacting the purified maytansinoid with a cell-bindingagent comprising a maleimido group or a haloacetyl group;

A method of esterification of maytansinol to give a maytansinoid of theformula 4₂′:

wherein:

Y₂′ represents(CR₇R₈)_(l)(CR₉═CR₁₀)_(p)(C≡C)_(q)A_(o)(CR₅R₆)_(m)D_(u)(CR₁₁═CR₁₂)_(r)(C≡C)_(s)B_(t)(CR₃R₄)_(n)CR₁R₂SZ₂,wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

A, B, and D each independently is cycloalkyl or cycloalkenyl having 3 to10 carbon atoms, simple or substituted aryl, or heterocyclic aromatic orheterocyclic radical;

R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, and R₁₂ are each independently H,CH₃, C₂H₅, linear alkyl or alkenyl having from 1 to 10 carbon atoms,branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms,phenyl, substituted phenyl or heterocyclic aromatic or heterocyclicradical;

l, m, n, o, p, q, r, s, t and u are each independently 0 or an integerof from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s, tand u are not zero at any one time; and

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3-10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical, said method comprising reacting maytansinol of thestructure 11 at the C-3:

with a compound of formula (III′-L), (III′-D), or (III′-D, L):

wherein:

Y_(2′) represents(CR₇R₈)_(l)(CR₉═CR₁₀)_(p)(C≡C)_(q)A_(o)(CR₅R₆)_(m)D_(u)(CR₁₁═CR₁₂)_(r)(C≡C)_(s)B_(t)(CR₃R₄)_(n)CR₁R₂SZ₂,wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

A, B, and D each, independently is cycloalkyl or cycloalkenyl having3-10 carbon atoms, simple or substituted aryl, or heterocyclic aromaticor heterocyclic radical;

R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₉, R₁₁, and R₁₂ are each independently H,CH₃, C₂H₅, linear alkyl or alkenyl having from 1 to 10 carbon atoms,branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms,phenyl, substituted phenyl or heterocyclic aromatic or heterocyclicradical;

l, m, n, o, p, q, r, s, t and u are each independently 0 or an integerof from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s, tand u are not zero at any one time; and

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical.

The method of esterification of maytansinol to give a maytansinoid ofthe formula 4₂′, wherein the compound of formula (I) is represented byformula (I-L).

The method of esterification of maytansinol to give a maytansinoid ofthe formula 4₂′, wherein R₁ is H and R₂ is methyl,

A method of esterification of maytansinol to give a maytansinoid of theformula 4₂:

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, cyclic alkyl or alkenyl having from 3to 10 carbon atoms, phenyl, substituted phenyl, or heterocyclic aromaticor heterocyclic radical, and in addition R₂ can be H;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0;

Z₂ is SR or COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical, said method comprising reacting maytansinol of thestructure 11:

at the C-3 position with a compound of formula (III-L), (III-D), or(III-D, L):

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0;

Z₂ is SR or COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical;

The above-described method of esterification of maytansinol to give themaytansinoid of formula 4a, wherein the compound of formula (III) isrepresented by formula (III-L);

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4a, wherein said compound of formula (III-L) iscompound 15a(S,S), 15b(S,R) or a mixture of 15a(S,S) and 15b(S,R);

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4a, wherein said compound of formula (III-D) iscompound 15(R,S), 15(R,R), or a mixture of 15(R,S) and 15(R,R);

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4a, wherein said compound of formula (III-D,L)is racemic N-methylalanine acylated with a carboxylic group bearing aprotected thiol functionality, in which the carbon center bearing thesulfur atom is either racemic or of R or S chirality to give compoundsof the structure of 15;

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4a, wherein the mixture of 15a(S,S) and15b(S,R) is made by a process comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with N-methyl-L-alanine to give said mixture ofcompounds 15a(S,S) and 15b(S,R);

The above-described method of esterification of maytansinol, whereinsaid compound 15a(S,S) is made by a method comprising:

(1) converting (R)-1,3-butanediol into (S)-4-(methydithio)pentanoic acid19;

(2) converting compound 19 into its N-hydroxysuccinimide ester (20); and

(3) reacting compound 20 with N-methyl-L-alanine to give the compound15a(S,S).

The above-described method of esterification of maytansinol, whereinsaid compound 15b(S,R) is made by a method comprising:

(1) converting (S)-1,3-butanediol into (R)-4-(methydithio)pentanoic acid24;

(2) converting compound 24 into its N-hydroxysuccinimide ester (25); and

(3) reacting compound 25 with N-methyl-L-alanine to give the compound15b(S,R);

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4a, wherein the mixture of compounds 15(R,S)and 15(R,R) can be made by a process comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with N-methyl-D-alanine to give said mixture ofcompounds 15(R,S) and 15(R,R).

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4a, wherein racemic N-methylalanine acylatedwith a carboxylic group bearing a protected thiol functionality, inwhich the carbon center bearing the sulfur atom is either racemic or ofthe R or S chirality to give compounds of the structure of 15 is made bya process comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with racemic N-methylalanine to give theracemic N-methylalanine acylated with a carboxylic group bearing aprotected thiol functionality, in which the carbon center bearing thesulfur atom is either racemic or of the R or S chirality to givecompounds of the structure 15.

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4b, wherein R₁ and R₂ are methyl; R₅, R₆, R₇,R₈ are each H; l and m are 1; and n is 0;

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4b, wherein said compound of formula (III-L) iscompound 10 containing N-methyl-L-alanine;

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4b, wherein said compound of formula (III-D) iscompound 10 containing N-methyl-D-alanine;

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4b, wherein said compound of formula (III-D,L)is compound 10 containing racemic N-methylalanine;

The above-described method of esterification of maytansinol to givemaytansinoids of formula 4b, wherein the compound 10 containingN-methyl-L-alanine, N-methyl-D-alanine or racemic N-methylalanine ismade by a process comprising:

(1) reacting isobutylene sulfide (5) with the anion of acetonitrile togive compound 6;

(2) hydrolyzing compound 6 to give 4-mercapto-4-methylpentanoic acid(7);

(3) converting compound 7 into the disulfide 8 by reaction with methylmethanethiolsulfonate;

(4) converting compound 8 into its N-hydroxysuccinimide ester 9; and

(5) reacting compound 9 with N-methyl-L-alanine, N-methyl-D-alanine, orracemic N-methylalanine to give compound 10 containingN-methyl-L-alanine, N-methyl-D-alanine or racemic N-methylalanine;

The above-described method of esterification of maytansinol with 10,followed by separating diastereomers, if present, and purifying themaytansinoid by HPLC on cyano-bonded silica, further comprisingreduction of the disulfide bond, to give maytansinoids of formula 4b;

A method of making a maytansinoid-cell-binding agent conjugatecomprising making a purified maytansinoid by any of the above-describedmethods of esterification of maytansinol to give maytansinoids offormula 4b, and reacting the maytansinoid with a cell-binding agentcomprising a sulfhydryl group or a reactive dithio group, preferably, adithiopyridyl group or a substituted dithiopyridyl group;

A method of making a maytansinoid-cell-binding agent conjugatecomprising making a purified maytansinoid by any of the above-describedmethods of esterification of maytansinol to give maytansinoids offormula 4b, and reacting the maytansinoid with a cell-binding agentcomprising a maleimido or an haloacetyl group.

Methods of therapy using the above-described conjugates.

Compounds of formula (III):

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(N)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl, orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0; and

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical.

Compounds 10(S), 10(R) or racemic 10;

A method of making compound 10 containing N-methyl-L-alanine,N-methyl-D-alanine, or racemic N-methylalanine comprising:

(1) reacting isobutylene sulfide (5) with the anion of acetonitrile togive compound 6;

(2) hydrolyzing compound 6 to give 4-mercapto-4-methylpentanoic acid(7);

(3) converting compound 7 into disulfide 8 by reaction withmethylmethanethiolsulfonate;

(4) converting compound 8 into its N-hydroxysuccinimide ester 9; and

(5) reacting compound 9 with N-methyl-L-alanine, N-methyl-D-alanine, orracemic N-methylalanine to give said compound 10 containingN-methyl-L-alanine, N-methyl-D-alanine, or racemic N-methylalanine

A mixture of compounds 15a(S,S) and 15b(S,R);

A method of making a mixture of compounds 15a(S,S) and 15b(S,R),comprising:

(1) reacting 4-mercaptopentanoic acid (12) withmethylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester (14); and

(3) reacting compound 14 with N-methyl-L-alanine to give said mixture ofcompounds 15a(S,S) and 15b(S,R);

A mixture of compounds 15(R,S) and 15(R,R).

A method of making a mixture of compounds 15(R,S) and 15(R,R)comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with N-methyl-D-alanine to give said mixture ofcompounds 15(R,S) and 15(R,R).

Racemic N-methylalanine acylated with a carboxylic group bearing aprotected thiol functionality, in which the carbon center bearing thesulfur atom is either racemic or of the R or S chirality to givecompounds of the structure of 15.

A method of making racemic N-methylalanine acylated with a carboxylicgroup bearing a protected thiol functionality, in which the carboncenter bearing the sulfur atom is either racemic or of R or S chiralityto give compounds of the structure 15, comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with racemic N-methylalanine to give theracemic N-methylalanine acylated with a carboxylic group bearing aprotected thiol functionality, in which the carbon center bearing thesulfur atom is either racemic or of the R or S chirality to givecompounds of the structure 15.

Compound 15a(S,S);

Compound 15b(S,R);

A method of making compound 15a(S,S) comprising:

(1) converting (R)-1,3-butanediol into (S)-4-(methydithio)pentanoic acid19;

(2) converting compound 19 into its N-hydroxysuccinimide ester (20); and

(3) reacting compound 20 with N-methyl-L-alanine to give said compound15a(S,S);

A method of making compound 15b(S,R) comprising:

(1) converting (S)-1,3-butanediol into (R)-4-(methydithio)pentanoic acid24;

(2) converting compound 24 into its N-hydroxysuccinimide ester (25); and

(3) reacting compound 25 with N-methyl-L-alanine to give said compound15b(S,R).

A pharmaceutical composition comprising an effective amount of any ofthe above-described maytansinoid compounds, a pharmaceuticallyacceptable salt or solvate thereof, and a pharmaceutically acceptablecarrier, diluent or excipient;

The above-described pharmaceutical composition comprising a maytansinoidcompound, further comprising an antibody.

A method for inducing cell death in selected cell populations comprisingcontacting target cells or tissue containing target cells with aneffective amount of any of the above-described maytansinoid-cell-bindingagents, salts or solvates thereof.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the structures of previously described maytansinoids.

FIG. 2 shows the structures of some of the maytansinoids of the presentinvention.

FIGS. 3 a-d show schemes for the synthesis of representativemaytansinoids of the present invention.

FIGS. 4 a,b are graphs that show the in vitro potency of newmaytansinoids of the present invention.

FIGS. 4 c,d are graphs that compare the in vitro potency of newmaytansinoids of the present invention with those previously described.

FIGS. 5 a-d show schemes for the preparation of conjugates ofcell-binding agents with maytansinoids of the present invention.

FIG. 6 is a graph that shows the in vitro potency of cell-bindingagent-maytansinoid conjugates of the present invention.

FIG. 7 is a graph that compares the in vivo anti-tumor efficacy ofhuC242-maytansinoids of the present invention with huC42 conjugates ofpreviously described maytansinoids, against HT-29 human colon tumorxenografts.

FIG. 8 is a graph that compares the in vivo anti-tumor efficacy ofhuC242-maytansinoids of the present invention with huC242 conjugates ofpreviously described maytansinoids, against COLO 205 human colon tumorxenografts.

FIG. 9 is a graph that compares the in vivo anti-tumor efficacy ofMY9-6-maytansinoids of the present invention with MY9-6 conjugates ofpreviously described maytansinoids, against HL60 promyelocytic myeloidleukemia xenografts.

FIG. 10 shows the result of the in vitro cytotoxicity evaluation of theconjugate huMy9-6-DM4 with target HL-60 cells and non-target Namalwacells.

FIG. 11 shows the in vivo efficacy evaluation of the conjugatehuMy9-6-DM4 against human HL-60 xenograft tumors in SCID mice andcompares it with that of a huMy9-6 conjugate of a previously describedmaytansinoid (huMy9-6-DM1).

FIG. 12 shows the result of the in vitro cytotoxicity evaluation of theconjugate huB4-DM4 with target Ramos cells and non-target Colo 205cells.

FIG. 13 a shows the in vivo efficacy evaluation of the conjugatehuB4-DM4 against human Ramos xenograft tumors in SCID mice, and FIG. 13b shows the changes in the body weights of the animals during the testperiod.

DETAILED DESCRIPTION OF THE INVENTION

This invention discloses new, sterically hindered thiol anddisulfide-containing maytansinoids in which the α-carbon atom bearingthe sulfur atom bears one or two alkyl substituents. The invention alsodiscloses a process for the synthesis of these novel maytansinoids.Novel compounds that are useful as intermediates in the synthesis of thenew maytansinoids are further disclosed. In addition, this inventiondiscloses the preparation of conjugates of these novel maytansinoidswith cell-binding agents.

The art reveals that it is extremely difficult to modify existing drugswithout diminishing their cytotoxic potential. The disclosed inventionovercomes this problem by teaching a method of synthesizing newmaytansinoid molecules containing a sterically hindered thiol ordisulfide moiety. The disclosed novel maytansinoids preserve, and insome cases even enhance, the cytotoxic potency of the previouslydescribed maytansinoids.

The maytansinoid-cell-binding agent conjugates permit the full measureof the cytotoxic action of the maytansinoids to be applied in a targetedfashion against unwanted cells only, thereby avoiding side effects dueto damage to non-targeted healthy cells. Thus, the invention providesuseful agents, and novel methods for making the same, for theelimination of diseased or abnormal cells that are to be killed orlysed, such as tumor cells (particularly solid tumor cells), virusinfected cells, microorganism infected cells, parasite infected cells,autoimmune cells (cells that produce autoantibodies), activated cells(those involved in graft rejection or graft vs. host disease), or anyother type of diseased or abnormal cells, while exhibiting a minimum ofside effects.

Thus, this invention teaches a method for the production of improvedcytotoxic conjugates comprising novel maytansinoids and cell-bindingagents, with vastly improved biological activity as compared topreviously described maytansinoids and cell-binding agents.

The invention further teaches a method for the synthesis of maytansinoidderivatives that possess a sterically hindered thiol or disulfide moietythat allows chemical linkage to a cell-binding agent while displayinghigh cytotoxicity either in bound form or in released form or in bothstates. The cytotoxic conjugate according to the present inventioncomprises one or more maytansinoids linked to a cell-binding agent. Inorder to link the maytansinoid to a cell-binding agent, the maytansinoidmust first be modified.

Maytansinoids that can be used in the present invention to produce themaytansinoids that are capable of being linked to a cell-binding agentare well known in the art and can be isolated from natural sourcesaccording to known methods or prepared synthetically according to knownmethods.

Examples of suitable maytansinoids include maytansinol and maytansinolanalogues. Examples of suitable maytansinol analogues include thosehaving a modified aromatic ring and those having modifications at otherpositions.

Specific examples of suitable analogues of maytansinol having a modifiedaromatic ring include:

(1) C-19-dechloro (U.S. Pat. No. 4,256,746) (prepared by LAH reductionof ansamitocin P2);

(2) C-20-hydroxy (or C-20-demethyl)+/−C-19-dechloro (U.S. Pat. Nos.4,361,650 and 4,307,016) (prepared by demethylation using Streptomycesor Actinomyces or dechlorination using LAH); and

(3) C-20-demethoxy, C-20-acyloxy (—OCOR), +/−dechloro (U.S. Pat. No.4,294,757) (prepared by acylation using acyl chlorides).

Specific examples of suitable analogues of maytansinol havingmodifications of other positions include:

(1) C-9-SH (U.S. Pat. No. 4,424,219) (prepared by the reaction ofmaytansinol with H₂S or P₂S₅);

(2) C-14-alkoxymethyl (demethoxy/CH₂OR) (U.S. Pat. No. 4,331,598);

(3) C-14-hydroxymethyl or acyloxymethyl (CH₂OH or CH₂OAc) (U.S. Pat. No.4,450,254) (prepared from Nocardia);

(4) C-15-hydroxy/acyloxy (U.S. Pat. No. 4,364,866) (prepared by theconversion of maytansinol by Streptomyces);

(5) C-15-methoxy (U.S. Pat. Nos. 4,313,946 and 4,315,929) (isolated fromTrewia nudiflora);

(6) C-18-N-demethyl (U.S. Pat. Nos. 4,362,663 and 4,322,348) (preparedby the demethylation of maytansinol by Streptomyces); and

(7) 4,5-deoxy (U.S. Pat. No. 4,371,533) (prepared by the titaniumtrichloride/LAH reduction of maytansinol).

In order to link the maytansinoid to the cell-binding agent, themaytansinoid comprises a linking moiety. The linking moiety contains achemical bond that allows for the release of fully active maytansinoidsat a particular site. Suitable chemical bonds are well known in the artand include disulfide bonds, acid labile bonds, photolabile bonds,peptidase labile bonds and esterase labile bonds. Preferred aredisulfide bonds.

The disclosure of U.S. Pat. No. 5,208,020, incorporated herein byreference, teaches the production of maytansinoids bearing such bonds.

According to the present invention, the linking moiety comprises asterically hindered thiol or disulfide moiety.

Particularly preferred maytansinoids comprising a linking moiety thatcontains a reactive chemical group are C-3 esters of maytansinol and itsanalogs where the linking moiety contains a sterically hindered thiol ordisulfide bond.

Many positions on maytansinoids can serve as the position to chemicallylink the linking moiety. For example, the C-3 position having a hydroxylgroup, the C-14 position modified with hydroxymethyl, the C-15 positionmodified with hydroxy and the C-20 position having a hydroxy group areall expected to be useful. However the C-3 position is preferred and theC-3 position of maytansinol is especially preferred.

Further, while the synthesis of esters of maytansinol having a linkingmoiety is described below in terms of a disulfide bond containinglinking moieties at the C-3 position, one of skill in the art willunderstand that linking moieties with other chemical bonds, as describedabove, can also be used with the present invention, as can othermaytansinoids and other linking positions, as described above.

The structures of various maytansinoids of the present invention arerepresented in FIG. 2. The synthesis of maytansinoids having asterically hindered thiol or disulfide moiety can be described byreference to FIG. 3. Many of the exemplified methods below utilize thethiol-containing maytansinoidsN^(2′)-deacetyl-N-^(2′)(4-mercapto-1-oxopentyl)-maytansine (termed DM3)and N^(2′)-deacetyl-N-^(2′)(4-methyl-4-mercapto-1-oxopentyl)-maytansine(termed DM4). DM3 (4a) and DM4 (4b) are represented by the followingstructural formulae:

The in vitro cytotoxicity of the new sterically hindered thiol anddisulfide-containing maytansinoids of the invention can be evaluated fortheir ability to suppress proliferation of various unwanted cell linesin vitro (FIG. 4). For example, cell lines such as the human breastcarcinoma line SK-Br-3, or the human epidermoid carcinoma cell line KB,can be used for the assessment of cytotoxicity of these newmaytansinoids. Cells to be evaluated can be exposed to the compounds for72 hours and the surviving fractions of cells measured in direct assaysby known methods. IC₅₀ values can then be calculated from the results ofthe assays.

Production of Maytansinoids Having a Sterically Hindered Thiol orDisulfide Moiety

The novel maytansinoids of the invention are those having, at C-3, C-14hydroxymethyl, C-15 hydroxy, or C-20 desmethyl, an acylated amino acidside chain with an acyl group bearing a hindered sulfhydryl group,wherein the carbon atom of the acyl group bearing the thiolfunctionality has one or two substituents, said substituents being CH₃,C₂H₅, linear alkyl or alkenyl having from 1 to 10 carbon atoms, branchedor cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl,substituted phenyl or heterocyclic aromatic or heterocyclic radical, andin addition one of the substituents can be H, and wherein the acyl grouphas a linear chain length of at least three carbon atoms between thecarbonyl functionality and the sulfur atom.

Preferably, the maytansinoid compounds are represented by formula 4′:

wherein:

Y′ represents(CR₇R₈)_(l)(CR₉═CR₁₀)_(p)(C≡C)_(q)A_(o)(CR₅R₆)_(m)D_(u)(CR₁₁═CR₁₂)_(r)(C≡C)_(s)B_(t)(CR₃R₄)_(n)CR₁R₂SZ,wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH; A, B, D are cycloalkyl or cycloalkenyl having 3-10 carbon atoms,simple or substituted aryl or heterocyclic aromatic or heterocyclicradical;

R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₉, R₁₁, and R₁₂ are each independently H,CH₃, C₂H₅, linear alkyl or alkenyl having from 1 to 10 carbon atoms,branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms,phenyl, substituted phenyl or heterocyclic aromatic or heterocyclicradical;

l, m, n, o, p, q, r, s, t and u are each independently 0 or an integerof from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s, tand u are not zero at any one time;

Z is H, SR or —COR, wherein R is linear alkyl or alkenyl having from 1to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to10 carbon atoms, or simple or substituted aryl or heterocyclic aromaticor heterocyclic radical.

In a preferred embodiments of the compound represented by formula 4′, R₁is H, R₂ is methyl and Z is H; R₁ and R₂ are methyl and Z is H; R₁ is H,R₂ is methyl, and Z is —SCH₃; or R₁ and R₂ are methyl, and Z is —SCH₃.

More preferably, the maytansinoids are compounds represented by formula(I-L), (I-D), or (I-D,L):

wherein:Y represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, cyclic alkyl or alkenyl having from 3to 10 carbon atoms, phenyl, substituted phenyl, or heterocyclic aromaticor heterocyclic radical, and in addition R₂ can be H;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0;

Z is H, SR or —COR, wherein R is linear alkyl or alkenyl having from 1to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to10 carbon atoms, or simple or substituted aryl or heterocyclic aromaticor heterocyclic radical; and

May represents a maytansinoid which bears the side chain at C-3, C-14hydroxymethyl, C-15 hydroxy or C-20 desmethyl.

More preferred is the C-3 ester, which is a compound represented byformula 4:

wherein the substituents are as defined above.

Especially preferred are any of the above-described compounds, whereinR₁ is H, R₂ is methyl, R₅, R₆, R₇ and R₈ are each H, l and m are each 1,n is 0, and Z is H; those compounds wherein R₁ and R₂ are methyl, R₅,R₆, R₇, R₈ are each H, l and m are 1, n is 0, and Z is H; thosecompounds wherein R₁ is H, R₂ is methyl, R₅, R₆, R₇, and R₈ are each H,l and m are each 1, n is 0, and Z is —SCH₃; and those compounds R₁ andR₂ are methyl, R₅, R₆, R₇, R₈ are each H, l and m are 1, n is 0, and Zis —SCH₃. Further, the L-alanyl stereoisomer is preferred as it is themost useful for the conjugates of the invention.

Preferred embodiments of formula 4 include DM3 and DM4, i.e., themaytansinoid of formula 4 where Z is H, R₁ is H, R₂ is methyl, R₅, R₆,R₇, and R₈ are each H, and l and m are 1, and n is 0 (DM3, compound 4a);the maytansinoid of formula 4 where Z is H, R₁ and R₂ are both methyl,R₅, R₆, R₇, and R₈ are each H, l and m are 1, and n is 0 (DM4. compound4b); the maytansinoid of formula 4 wherein R₁ is H, R₂ is methyl, R₅,R₆, R₇, and R₈ are each H, l and m are each 1, n is 0, and Z is —SCH₃;and the maytansinoid of formula 4 wherein R₁ and R₂ are methyl, R₅, R₆,R₇, R₈ are each H, l and m are 1, n is 0, and Z is —SCH₃.

Examples of linear alkyls or alkenyls having from 1 to 10 carbon atomsinclude, but are not limited to, methyl, ethyl, propyl, butyl, pentyl,hexyl, propenyl, butenyl and hexenyl.

Examples of branched alkyls or alkenyls having from 3 to 10 carbon atomsinclude, but are not limited to, isopropyl, isobutyl, sec.-butyl,tert.-butyl, isopentyl, 1-ethyl-propyl, isobutenyl and isopentenyl.

Examples of cyclic alkyls or alkenyls having from 3 to 10 carbon atomsinclude, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cyclopentenyl, and cyclohexenyl.

Simple aryls include aryls having 6 to 10 carbon atoms, and substitutedaryls include aryls having 6 to 10 carbon atoms bearing at least onealkyl substituent containing from 1 to 4 carbon atoms, or alkoxysubstituent such as methoxy, ethoxy, or a halogen substituent or a nitrosubstituent.

Examples of simple aryl that contain 6 to 10 carbon atoms include phenyland naphthyl.

Examples of substituted aryl include nitrophenyl, dinitrophenyl.

Heterocyclic aromatic radicals include groups that have a 3 to10-membered ring containing one or two heteroatoms selected from N, O orS.

Heterocyclic alkyl radicals include cyclic compounds, comprising 3 to10-membered ring systems, containing one or two heteroatoms, selectedform N, O or S.

Examples of heterocyclic aromatic radicals include pyridyl,nitro-pyridyl, pyrollyl, oxazolyl, thienyl, thiazolyl, and furyl.

Examples of heteroalkyl radicals include dihydrofuryl, tetrahydrofuryl,tetrahydropyrollyl, piperidinyl, piperazinyl, and morpholino.

Novel maytansinoids having a sterically hindered thiol or disulfidemoiety may be prepared by the following newly disclosed methods:

Synthesis of Maytansinoids.

FIG. 3 a shows the steps in the synthesis of maytansinoid DM4 (4b).Isobutylene sulfide (5) is reacted with the anion of acetonitrile togive the mercapto compound 6. Hydrolysis of 6 with base provided4-mercapto-4-methylpentanoic acid (7). Conversion of 7 into disulfide 8is achieved by reaction with methyl methanethiolsulfonate (MeSSO₂Me).Conversion of 8 into the N-hydroxysuccinimide ester 9 followed byreaction with N-methyl-L-alanine provided the carboxylic acid 10, whichwas purified by column chromatography over silica gel. Reaction of 10with maytansinol (11) in the presence of N,N′-dicyclohexylcarbodiimide(DCC) and zinc chloride gave a mixture of the N-acyl-N-methyl-L-alanylmaytansinoid L-DM4SMe, (4e) and the N-acyl-N-methyl-D-alanylmaytansinoid D-DM4SMe (4f). The mixture of diastereomers was separatedby HPLC, using a cyano-bonded column. The desired L-aminoacid-containing isomer 4e was collected and reduced with dithiothreitolto give the thiol-containing L-aminoacyl maytansinoid DM4 (4b), whichwas again purified by HPLC, using a cyano-bonded column.

FIG. 3 b shows the steps in the synthesis of maytansinoid DM3 (4a).4-Mercaptopentanoic acid (12) was converted into the methyldisulfide byreaction with methyl methanethiolsulfonate to give 13. Conversion of 13into the N-hydroxysuccinimide ester 14 followed by reaction withN-methyl-L-alanine provided the carboxylic acid 15, which was purifiedby column chromatography over silica gel. Reaction of 15 withmaytansinol (11) in the presence of N,N′-dicyclohexylcarbodiimide (DCC)and zinc chloride gave a mixture of the N-acyl-N-methyl-L-alanylmaytansinoid L-DM3SSMe, (4c) and the N-acyl-N-methyl-D-alanylmaytansinoid D-DM3SSMe (4d). The mixture of diastereomers was separatedby HPLC, using a cyano-bonded column. The desired L-aminoacid-containing isomer was collected and reduced with dithiothreitol togive the mercapto-L-amino acid-containing maytansinoid DM3 (4a), whichwas again purified by HPLC, using a cyano-bonded column.

FIGS. 3 c and d show the synthesis of DM3 bearing

either the (S)-4-methyldithio-1-oxopentyl moiety or the(R)-4-methyldithio-1-oxo-pentyl moiety. Conversion or (R)-1,3-butanediol(16) into its ditosylate 17, followed by sequential reaction with sodiumcyanide and potassium ethyl xanthate gave nitrile 18 (FIG. 3 c). Basehydrolysis, followed by disulfide exchange gave(S)-4-methydithio-pentanoic acid 19. Conversion of 19 into thesuccinimidyl ester 20, followed by reaction with N-methyl-L-alanine gaveN-methyl-N-[4-(S)-methyldithio-1-oxo-pentyl]-S-alanine (15a). Reactionwith maytansinol, as described above for compound 15, gave the twodiastereomers of L-DM3SMe 4g and 4h. Similarly, (S)-1,3-butanediol (21)was converted into (R)-4-methydithio-pentanoic acid 24 and then into15b. Reaction with maytansinol, as described above, gave the twodiastereomers of DM3SMe, 4k and 4l.

Thus the present invention provides a method of esterification of amaytansinoid at C-3, C-14 hydroxymethyl, C-15 hydroxy, or C-20desmethyl, with an acylated amino acid side chain where the acyl groupbears a protected sulfhydryl group, wherein the carbon atom of the acylgroup bearing the protected thiol functionality has one or twosubstituents, said substituents being CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition one ofthe substituents can be H, and wherein the acyl group has a linear chainlength of at least three carbon atoms between the carbonyl functionalityand the sulfur atom, said method comprising reacting a maytansinoid atC-3, C-14 hydroxymethyl, C-15 hydroxy, or C-20 desmethyl, said methodcomprising reacting a maytansinoid at C-3, C-14 hydroxymethyl, C-15hydroxy, or C-20 desmethyl, with the acylated amino acid where the acylgroup bears a protected sulfhydryl group.

In a preferred embodiment, the present invention provides a method ofesterification of maytansinol to give a maytansinoid of the formula 4₂′:

wherein:

Y₂′ represents(CR₇R₈)_(l)(CR₉═CR₁₀)_(p)(C≡C)_(q)A_(o)(CR₅R₆)_(m)D_(u)(CR₁₁═CR₁₂)_(r)(C≡C)_(s)B_(t)(CR₃R₄)_(n)CR₁R₂SZ₂,wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

A, B, and D each independently is cycloalkyl or cycloalkenyl having 3-10carbon atoms, simple or substituted aryl, or heterocyclic aromatic orheterocyclic radical;

R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₉, R₁₁, and R₁₂ are each independently H,CH₃, C₂H₅, linear alkyl or alkenyl having from 1 to 10 carbon atoms,branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms,phenyl, substituted phenyl or heterocyclic aromatic or heterocyclicradical;

l, m, n, o, p, q, r, s, t and u are each independently 0 or an integerof from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s, tand u are not zero at any one time; and

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3-10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical, said method comprising reacting maytansinol of thestructure 11 at the C-3:

with a compound of formula (III′-L), (III′-D), or (III′-D, L):

wherein:

Y_(2′) represents(CR₇R₈)_(l)(CR₉═CR₁₀)_(p)(C≡C)_(q)A_(o)(CR₅R₆)_(m)D_(u)(CR₁₁═CR₁₂)_(r)(C≡C)_(s)B_(t)(CR₃R₄)_(n)CR₁R₂SZ₂,wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

A, B, and D each, independently is cycloalkyl or cycloalkenyl having3-10 carbon atoms, simple or substituted aryl, or heterocyclic aromaticor heterocyclic radical;

R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, and R₁₂ are each independently H,CH₃, C₂H₅, linear alkyl or alkenyl having from 1 to 10 carbon atoms,branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms,phenyl, substituted phenyl or heterocyclic aromatic or heterocyclicradical;

l, m, n, o, p, q, r, s, t and u are each independently 0 or an integerof from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s, tand u are not zero at any one time; and

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical.

Preferably, the compound of formula (I) is represented by formula (I-L)and, also preferable, R₁ is H and R₂ is methyl.

In a more preferred embodiment, the present invention provides A methodof esterification of maytansinol to give a maytansinoid of the formula4₂:

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0;

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical, said method comprising reacting maytansinol of thestructure 11 at the C-3:

with a compound represented by formula (III-L), (III-D), or (III-D,L):

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl, orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0; and

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical.

The diastereomers can be separated by HPLC on cyano-bonded silica.

In a more preferred embodiment, the present invention provides a methodof esterification of a maytansinoid to produce a maytansinoid esterrepresented by formula (IV-L), (IV-D), or (IV-D,L):

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl, orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0;

Z₂ is SR or COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3-10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical; and

May is a maytansinoid; said method comprising reacting said may at C-3,C-14 hydroxymethyl, C-15 hydroxy, or C-20 desmethyl, with a compound offormula (III-L), (III-D), or (III-D,L):

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0; and

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical.

In an even more preferred embodiment the present invention provides amethod of esterification of maytansinol to give a maytansinoid of theformula 4₂:

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0;

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3-10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical, said method comprising reacting maytansinol at theC-3 with a compound of formula (III-L), (III-D), or (III-D, L):

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0;

Z₂ is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10carbon atoms, or simple or substituted aryl or heterocyclic aromatic orheterocyclic radical.

Preferably, the compound represented by the formula (I) is the Lstereoisomer.

For the above methods, it is preferred that R₁ is H, R₂ is methyl, R₅,R₆, R₇, and R₈ are each H, l and m are each 1, and n is 0; or that R₁and R₂ are methyl, R₅, R₆, R₇ and R₈ are each H, l and m are 1, and n is0.

When making DM3, the compound of formula (III-L) is 15a(S,S), 15b(S,R)or a mixture of 15a(S,S) and 15b(S,R); the compound of formula (III-D)is N-methyl-D-alanine acylated with the racemic acyl group or with theacyl group having either R or S chirality to give compounds 15; and thecompound of formula (III-D,L) is racemic N-methylalanine acylated with acarboxylic group bearing a protected thiol functionality, in which thecarbon center bearing the sulfur atom is either racemic or of the R or Schirality to give compounds of the structure of 15.

The mixture of 15a(S,S) and 15b(S,R) can be made by a processcomprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with N-methyl-L-alanine to give said mixture ofcompounds 15a(S,S) and 15b(S,R).

Similarly, the mixture of compounds 15(R,S) and 15(R,R) can be made by aprocess comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with N-methyl-D-alanine to give said mixture ofcompounds 15(R,S) and 15(R,R).

Racemic N-methylalanine acylated with a carboxylic group bearing aprotected thiol functionality, in which the carbon center bearing thesulfur atom is either racemic or of R or S chirality to give compoundsof the structure 15 can be made by a process comprising:

(1) reacting 4-mercaptopentanoic acid (12) with methylmethanethiolsulfonate to give compound 13;

(2) converting compound 13 into its N-hydroxysuccinimide ester 14;

(3) reacting compound 14 with racemic N-methylalanine to give saidracemic N-methylalanine acylated with a carboxylic group bearing aprotected thiol functionality, in which the carbon center bearing thesulfur atom is either racemic or of the R or S chirality to givecompounds of the structure 15.

The compound 15a(S,S) can be made by a process comprising:

(1) converting (R)-1,3-butanediol into (S)-4-(methydithio)pentanoic acid19;

(2) converting compound 19 into its N-hydroxysuccinimide ester (20); and

(3) reacting compound 20 with N-methyl-L-alanine to give said compound15a(S,S).

The compound 15b(S,R) can be made by a process comprising:

(1) converting (S)-1,3-butanediol into (R)-4-(methydithio)pentanoic acid24;

(2) converting compound 24 into its N-hydroxysuccinimide ester (25); and

(3) reacting compound 25 with N-methyl-L-alanine to give said compound15b(S,R).

When making DM4, the compound of formula (III-L) is a compound 10containing N-methyl-L-alanine; the compound of formula (III-D) iscompound 10 containing N-methyl-D-alanine, and the compound of formula(III-D,L) is compound 10 containing racemic N-methylalanine

The compound 10 containing N-methyl-L-alanine, N-methyl-D-alanine, orracemic N-methylalanine is made by a process comprising:

(1) reacting isobutylene sulfide (5) with the anion of acetonitrile togive compound 6;

(2) hydrolyzing compound 6 to give 4-mercapto-4-methylpentanoic acid(7);

(3) converting compound 7 into disulfide 8 by reaction withmethylmethanethiolsulfonate;

(4) converting compound 8 into its N-hydroxysuccinimide ester 9; and

(5) reacting compound 9 with N-methyl-L-alanine, N-methyl-D-alanine, orracemic N-methylalanine to give compound 10 containingN-methyl-L-alanine, N-methyl-D-alanine, or racemic N-methylalanine

According to the present invention, compounds of formula III are alsonew:

wherein:Y₂ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ₂, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0; and

Z₂ is SR or —COR, wherein R is linear alkyl, branched alkyl or cyclicalkyl having from 1 to 10 carbon atoms, or simple or substituted aryl orheterocyclic aromatic or heterocyclic radical.

The compounds of formula III can be made readily by one of ordinaryskill in the art by methods analogous to those disclosed herein formaking compounds 10 and 15.

In Vitro Cytotoxicity of Maytansinoids

The in vitro cytotoxicity of maytansinoids of the present invention isshown in FIG. 4. The new maytansinoids (4c, 4e) bearing a hindereddisulfide bond are highly potent towards the cell lines tested. Thus 4ckills A-375 cells and SK-Br-3 cells with IC₅₀ values of 1.5×10⁻¹¹ M and7.0×10⁻¹² M respectively. Similarly, maytansinoid 4e is also highlypotent with IC₅₀ values of 3.2×10⁻¹¹ M and 9.0×10⁻¹² M towards A-375 andSK-Br-3 cells respectively. Comparison of the in vitro potency of thehindered thiol-containing maytansinoid 4a of the present invention withthat of previously described maytansinoid 1 (FIG. 4 c,d), indicates thatthe new maytansinoids are 20 to 50-fold more potent than the previousdescribed ones.

Preparation of Cell-Binding Agents

The effectiveness of the compounds of the invention as therapeuticagents depends on the careful selection of an appropriate cell-bindingagent. Cell-binding agents may be of any kind presently known, or thatbecome known and include peptides and non-peptides. Generally, these canbe antibodies (especially monoclonal antibodies), lymphokines, hormones,growth factors, vitamins, nutrient-transport molecules (such astransferrin), or any other cell-binding molecule or substance.

More specific examples of cell-binding agents that can be used include:

polyclonal antibodies;

monoclonal antibodies;

fragments of antibodies such as Fab, Fab′, and F(ab′)₂, Fv (Parham, J.Immunol. 131:2895-2902 (1983); Spring et al. J. Immunol. 113:470-478(1974); Nisonoff et al. Arch. Biochem. Biophys. 89:230-244 (1960));

interferons (e.g. alpha., .beta., .gamma.);

lymphokines such as IL-2, IL-3, IL-4, IL-6;

hormones such as insulin, TRH (thyrotropin releasing hormone), MSH(melanocyte-stimulating hormone), steroid hormones, such as androgensand estrogens;

growth factors and colony-stimulating factors such as EGF, TGF-alpha,FGF, VEGF, G-CSF, M-CSF and GM-CSF (Burgess, Immunology Today 5:155-158(1984));

transferrin (O'Keefe et al. J. Biol. Chem. 260:932-937 (1985)); and

vitamins, such as folate.

Monoclonal antibody techniques allow for the production of extremelyspecific cell-binding agents in the form of specific monoclonalantibodies. Particularly well known in the art are techniques forcreating monoclonal antibodies produced by immunizing mice, rats,hamsters or any other mammal with the antigen of interest such as theintact target cell, antigens isolated from the target cell, whole virus,attenuated whole virus, and viral proteins such as viral coat proteins.Sensitized human cells can also be used. Another method of creatingmonoclonal antibodies is the use of phage libraries of scFv (singlechain variable region), specifically human scFv (see e.g., Griffiths etal., U.S. Pat. Nos. 5,885,793 and 5,969,108; McCafferty et al., WO92/01047; Liming et al., WO 99/06587). In addition, resurfacedantibodies disclosed in U.S. Pat. No. 5,639,641 may also be used, as mayhumanized antibodies.

Selection of the appropriate cell-binding agent is a matter of choicethat depends upon the particular cell population that is to be targeted,but in general human monoclonal antibodies are preferred if anappropriate one is available.

For example, the monoclonal antibody MY9 is a murine IgG₁ antibody thatbinds specifically to the CD33 Antigen {J. D. Griffin et al 8 LeukemiaRes., 521 (1984)} and can be used if the target cells express CD33 as inthe disease of acute myelogenous leukemia (AML). Similarly, themonoclonal antibody anti-B4 is a murine IgG₁, that binds to the CD19antigen on B cells {Nadler et al, 131 J. Immunol. 244-250 (1983)} andcan be used if the target cells are B cells or diseased cells thatexpress this antigen such as in non-Hodgkin's lymphoma or chroniclymphoblastic leukemia. Similarly, the monoclonal antibody, C242, thatbinds to the CanAg antigen, (U.S. Pat. No. 5,552,293) can be used totreat CanAg expressing tumors, such us colorectal, pancreatic andgastric cancers.

Additionally, GM-CSF, which binds to myeloid cells can be used as acell-binding agent to diseased cells from acute myelogenous leukemia.IL-2 which binds to activated T-cells can be used for prevention oftransplant graft rejection, for therapy and prevention ofgraft-versus-host disease, and for treatment of acute T-cell leukemia.MSH, which binds to melanocytes, can be used for the treatment ofmelanoma. Folic acid can be used to target the folate receptor expressedon ovarian and other tumors. Epidermal growth factor can be used totarget squamous cancers such as lung and head and neck. Somatostatin canbe used to target neuroblastomas and other tumor types.

Cancers of the breast and testes can be successfully targeted withestrogen (or estrogen analogues) or androgen (or androgen analogues)respectively as cell-binding agents.

Production of Cytotoxic Conjugates

The present invention also provides a maytansinoid-cell-binding agentconjugate comprising at least one maytansinoid linked to thecell-binding agent, wherein the cell-binding agent is linked to themaytansinoid using the thiol or disulfide functionality that is presenton the acyl group of an acylated amino acid side chain found at C-3,C-14 hydroxymethyl, C-15 hydroxy or C-20 desmethyl of the maytansinoid,and wherein the acyl group of the acylated amino acid side chain has itsthiol or disulfide functionality located at a carbon atom that has oneor two substituents, said substituents being CH₃, C₂H₅, linear alkyl oralkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl oralkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition one ofthe substituents can be H, and wherein the acyl group has a linear chainlength of at least three carbon atoms between the carbonyl functionalityand the sulfur atom.

A preferred cell-binding agent conjugate comprises at least onemaytansinoid linked to a cell-binding agent, wherein the maytansinoid isrepresented by formula 4₁′:

wherein:

Y₁′ represents(CR₇R₈)_(l)(CR₉═CR₁₀)_(p)(C≡C)_(q)A_(o)(CR₅R₆)_(m)D_(u)(CR₁₁═CR₁₂)_(r)(C≡C)_(s)B_(t)(CR₃R₄)_(n)CR₁R₂S—,wherein: R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl oralkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl oralkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl orheterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

A, B, and D, each independently is cycloalkyl or cycloalkenyl having3-10 carbon atoms, simple or substituted aryl, or heterocyclic aromaticor heterocyclic radical;

R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, and R₁₂ are each independently H,CH₃, C₂H₅, linear alkyl or alkenyl having from 1 to 10 carbon atoms,branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms,phenyl, substituted phenyl or heterocyclic aromatic or heterocyclicradical; and

l, m, n, o, p, q, r, s, t and u are each independently 0 or an integerof from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s, tand u are non-not zero at any one time.

Preferably, R₁ is H and R₂ is methyl. or R₁ and R₂ are methyl.

An even more preferred cell-binding agent conjugate comprises at leastone maytansinoid linked to the cell-binding agent, wherein themaytansinoid is represented by formula (II-L), (H-D), or (II-D,L):

wherein:Y₁ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂S—, wherein:

R₁ and R₂ are each independently CH₃, C₂H₅, linear alkyl or alkenylhaving from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenylhaving from 3 to 10 carbon atoms, phenyl, substituted phenyl,heterocyclic aromatic or heterocyclic radical, and in addition R₂ can beH;

R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, CH₃, C₂H₅, linearalkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclicalkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical;

l, m and n are each independently an integer of from 1 to 5, and inaddition n can be 0; and

May represents a maytansinol which bears the side chain at C-3, C-14hydroxymethyl, C-15 hydroxy or C-20 desmethyl.

Even more preferred is a maytansinoid-cell-binding agent conjugate,wherein the maytansinoid is represented by formula 4₁:

wherein the substituents are as defined for formula (II) above.

Especially preferred are any of the above-described compounds, whereinR₁ is H, R₂ is methyl, R₅, R₆, R₇ and R₈ are each H, l and m are each 1,and n is 0; and those wherein R₁ and R₂ are methyl, R₅, R₆, R₇, R₈ areeach H, l and m are 1, and n is 0.

Further, the L-aminoacyl stereoisomer is preferred.

Representational cytotoxic conjugates of the invention areantibody/maytansinoid, antibody fragment/maytansinoid, epidermal growthfactor (EGF)/maytansinoid, melanocyte stimulating hormone(MSH)/maytansinoid, thyroid stimulating hormone (TSH)/maytansinoid,somatostatin/maytansinoid, folate/maytansinoid, estrogen/maytansinoid,estrogen analogue/maytansinoid, androgen/maytansinoid, and androgenanalogue/maytansinoid.

The thiol-containing maytansinoid is reacted with an appropriatelymodified cell-binding agent to produce cytotoxic conjugates. Theseconjugates may be purified by gel-filtration, ion exchangechromatography, or by HPLC.

Schemes for preparing conjugates from sulfhydryl group-containingmaytansinoids are shown in FIG. 5. More specifically (FIG. 5 a, b), asolution of an antibody in aqueous buffer may be incubated with a molarexcess of an antibody modifying agent such asN-succinimidyl-3-(2-pyridyldithio)propionate (SPDP, 3a) to introducedithiopyridyl groups (FIG. 5 a). or withN-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB, 3b) to introducedithiopyridyl groups (FIG. 5 b). The modified antibody is then reactedwith the thiol-containing maytansinoids (such as 4a or 4b) to produce adisulfide-linked antibody-maytansinoid conjugate. Themaytansinoid-antibody conjugate may then be purified by gel-filtration.

Alternatively, the antibody may be incubated with a molar excess of anantibody modifying agent such as 2-iminothiolane to introduce sulfhydrylgroups. The modified antibody is then reacted with the appropriatedisulfide-containing maytansinoids to produce a disulfide-linkedantibody-maytansinoid conjugate. The maytansinoid-antibody conjugate maythen be purified by gel-filtration.

The number of maytansinoid molecules (denoted with w in FIGS. 5 a to 5d) bound per antibody molecule can be determined by measuringspectrophotometrically the ratio of the absorbance at 252 nm and 280 nm.An average of 1-10 maytansinoid molecules/antibody molecule can belinked by this method. The preferred average number of linkedmaytansinoid molecules per antibody molecule is 2-5, and the mostpreferred is 3-4.5.

Alternatively, a solution of an antibody in aqueous buffer may beincubated with a molar excess of an antibody-modifying agent such asN-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC,26) to introduce maleimido groups (FIG. 5 c), or withN-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB, 27) to introduceiodoacetyl groups (FIG. 5 d). The modified antibody is then reacted withthe thiol-containing maytansinoids (such as 4a or 4b) to produce athioether-linked antibody-maytansinoid conjugate. Themaytansinoid-antibody conjugate may then be purified by gel-filtration.

The number of maytansinoid molecules bound per antibody molecule can bedetermined by spectrophotometric analysis as described above.

Thus, the present invention provides a method of making amaytansinoid-cell-binding agent conjugate comprising making a purifiedmaytansinoid by one of the methods described above, and reacting thepurified maytansinoid with a cell-binding agent comprising a reactivedithio or a sulfhydryl group. Preferably, the reactive dithio group is adithiopyridyl group or a substituted dithiopyridyl group. Especiallypreferably, the reactive dithio group comprises a nitropyridyldithio ordinitropyridyldithio group.

In another method, the purified maytansinoid is reacted with acell-binding agent comprising a maleimido group or a haloacetyl group.

Conjugates of cell-binding agents with maytansinoid drugs of theinvention can be evaluated for their ability to suppress proliferationof various unwanted cell lines in vitro (FIG. 6). For example, celllines such as the human colon carcinoma line COLO 205, the humanmelanoma cell line A-375, the human myeloid leukemia cell line HL60 canbe used for the assessment of cytotoxicity of these conjugates. Cells tobe evaluated can be exposed to the compounds for 24 hours and thesurviving fractions of cells measured in direct assays by known methods.IC₅₀ values can then be calculated from the results of the assays.

The in vitro potency and target specificity of antibody-maytansinoidconjugates of the present invention are shown in FIGS. 6, 10 and 12.Thus, FIG. 6 shows that both huC242-DM3 and huC242-DM4 are highly potentin killing antigen positive COLO 205 cells, with IC₅₀ values of1.3×10⁻¹¹ M and 1.1×10⁻¹¹ M respectively. In contrast, antigen negativeA-375 cells are about 500-fold less sensitive demonstrating thatmaytansinoid conjugates of the present invention are highly potent andspecific. Similarly, FIGS. 10 and 12 demonstrate the high potency andtarget specificity of conjugates of the maytansinoids of the presentinvention, with the antibodies MY9-6 and anti-B4 respectively.

The in vivo anti-tumor efficacy of conjugates of antibodies with thehindered thiol-containing maytansinoids of the present invention wascompared with that of previously described maytansinoid conjugates inseveral different human tumor models in mice. In the first model (FIG.7), SCID mice bearing established subcutaneous human colon tumor HT-29xenografts were treated either with the antibody conjugate (huC242-DM1)of the previously described maytansinoid DM1, or with the two newmaytansinoid conjugates (huC242-DM3, huC242-DM4). Treatment withhuC242-DM1 resulted in a tumor growth delay of 18 days. In contrast, thenew agents were significantly more efficacious, with tumor growth delaysof 28 days for huC242-DM3 and 36 days for huC242-DM4.

In the second model (FIG. 8), mice bearing established subcutaneoushuman colon tumor COLO 205 xenografts were treated either with theantibody conjugate (huC242-DM1) of the previously described maytansinoidDM1, or with the two new maytansinoid conjugates (huC242-DM3,huC242-DM4). Treatment with huC242-DM1 did not result in tumorregression and gave a tumor growth delay of 20 days. In contrast, thenew agents were significantly more efficacious. Complete tumorregression lasting 45 days was achieved in the group treated withhuC242-DM3. huC242-DM4 was even more efficacious resulting in cures ofall the treated mice.

In the third model (FIG. 9), mice bearing established subcutaneous humanmyeloid leukemia HL60 xenografts were treated either with the antibodyconjugate (MY-9-6-DM1) of the previously described maytansinoid DM1, orwith the two new maytansinoid conjugates (MY9-6-DM3, MY9-6-DM4).Treatment with MY9-6-DM1 did not result in tumor regression and gave atumor growth delay of 5 days. In contrast, the new agents weresignificantly more efficacious. Resulting in tumor regression. BothMY9-6-DM3 and MY-9-6-DM4 gave tumor growth delays of greater than 20days.

In the fourth model (FIG. 11), a maytansinoid of the present invention(huMY9-6-DM4) was directly compared with that of a conjugate of thepreviously described maytansinoid (huMY9-6-DM1) in a subcutaneousxenograft model, established with HL-60 cells. At an equivalent dose,treatment with the conjugate of the current invention, MY9-6-DM4,results complete tumor regression lasting 85 days. In contrast, theconjugate of the previously described maytansinoid is much less activewith a tumor growth delay of only about 48 days.

In the fifth model (FIG. 13 a), a conjugate of a maytansinoid of thepresent invention with the huB4 antibody shows high anti-tumor activityin a dose-dependent manner in a subcutaneous Ramos tumor model. Completetumor regressions and cures are achieved at doses that are non-toxic(FIG. 13 a,b).

Results from the above five efficacy experiments demonstrate that thesterically hindered thiol-containing maytansinoids of the presentinvention give cell-binding agent conjugates with vastly improvedanti-tumor activity compared to the previously describedmaytansinoid-cell-binding agent conjugates.

Compositions and Methods of Use

The present invention provides pharmaceutical compositions comprising aneffective amount of any of the maytansinoid-cell-binding agents of thepresent invention, pharmaceutically acceptable a salt or solvatethereof, and a pharmaceutically acceptable carrier, diluent orexcipient.

The present invention also provides methods of treatment comprisingadministering to a subject in need of treatment an effective amount ofany of the conjugates described above.

Similarly, the present invention provides a method for inducing celldeath in selected cell populations comprising contacting target cells ortissue containing target cells with an effective amount of a cytotoxicagent comprising any of the maytansinoid-cell-binding agents of thepresent invention, a salt or solvate thereof. The target cells are cellsto which the cell-binding agent can bind.

If desired, other active agents, such as other anti-tumor agents, may beadministered along with the conjugate.

Suitable pharmaceutically acceptable carriers, diluents, and excipientsare well known and can be determined by those of ordinary skill in theart as the clinical situation warrants.

Examples of suitable carriers, diluents and/or excipients include: (1)Dulbecco's phosphate buffered saline, pH about 7.4, containing or notcontaining about 1 mg/ml to 25 mg/ml human serum albumin, (2) 0.9%saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose; and may also containan antioxidant such as tryptamine and a stabilizing agent such as Tween20.

The method for inducing cell death in selected cell populations can bepracticed in vitro, in vivo, or ex vivo.

Examples of in vitro uses include treatments of autologous bone marrowprior to their transplant into the same patient in order to killdiseased or malignant cells: treatments of bone marrow prior to theirtransplantation in order to kill competent T cells and preventgraft-versus-host-disease (GVHD); treatments of cell cultures in orderto kill all cells except for desired variants that do not express thetarget antigen; or to kill variants that express undesired antigen.

The conditions of non-clinical in vitro use are readily determined byone of ordinary skill in the art.

Examples of clinical ex vivo use are to remove tumor cells or lymphoidcells from bone marrow prior to autologous transplantation in cancertreatment or in treatment of autoimmune disease, or to remove T cellsand other lymphoid cells from autologous or allogenic bone marrow ortissue prior to transplant in order to prevent GVHD. Treatment can becarried out as follows. Bone marrow is harvested from the patient orother individual and then incubated in medium containing serum to whichis added the cytotoxic agent of the invention, concentrations range fromabout 10 μM to 1 μM, for about 30 minutes to about 48 hours at about 37°C. The exact conditions of concentration and time of incubation, i.e.,the dose, are readily determined by one of ordinary skill in the art.After incubation the bone marrow cells are washed with medium containingserum and returned to the patient intravenously according to knownmethods. In circumstances where the patient receives other treatmentsuch as a course of ablative chemotherapy or total-body irradiationbetween the time of harvest of the marrow and reinfusion of the treatedcells, the treated marrow cells are stored frozen in liquid nitrogenusing standard medical equipment.

For clinical in vivo use, the cytotoxic agent of the invention will besupplied as a solution or a lyophilized powder that are tested forsterility and for endotoxin levels. Examples of suitable protocols ofconjugate administration are as follows. Conjugates are given weekly for4 weeks as an intravenous bolus each week. Bolus doses are given in 50to 1000 ml of normal saline to which 5 to 10 ml of human serum albumincan be added. Dosages will be 10 μg to 2000 mg per administration,intravenously (range of 100 ng to 20 mg/kg per day). After four weeks oftreatment, the patient can continue to receive treatment on a weeklybasis. Specific clinical protocols with regard to route ofadministration, excipients, diluents, dosages, times, etc., can bedetermined by one of ordinary skill in the art as the clinical situationwarrants.

Examples of medical conditions that can be treated according to the invivo or ex vivo methods of inducing cell death in selected cellpopulations include malignancy of any type including, for example,cancer of the lung, breast, colon, prostate, kidney, pancreas, ovary,and lymphatic organs; autoimmune diseases, such as systemic lupus,rheumatoid arthritis, and multiple sclerosis; graft rejections, such asrenal transplant rejection, liver transplant rejection, lung transplantrejection, cardiac transplant rejection, and bone marrow transplantrejection; graft versus host disease; viral infections, such as CMVinfection, HIV infection, AIDS, etc.; and parasite infections, such asgiardiasis, amoebiasis, schistosomiasis, and others as determined by oneof ordinary skill in the art.

EXAMPLES

The invention will now be illustrated by reference to non-limitingexamples. Unless otherwise stated, all percents, ratios, parts, etc. areby weight. The examples described below are for compounds where R₁ isCH₃, R₂ is H, R₅, R₆, R₇, R₈ are each H, l and m are each 1, and n is 0.Similar synthesis can be carried out for other compounds of theinvention where R₁ and R₂ are each independently H, CH₃, C₂H₅, or higheralkyl, alkenyl, having from 1 to 10 carbon atoms, or phenyl, substitutedphenyl or heterocyclic aromatic or heterocyclic radical; and where l, mand n are each integers from 1 to 5, and in addition, n can also be 0.

All reagents were purchased from the Aldrich Chemical Co., New Jersey,or other commercial sources. Maytansinol (11) was prepared as describedpreviously (U.S. Pat. No. 6,333,410). Nuclear Magnetic Resonance (¹HNMR) spectra were acquired on a Bruker 400 MHz instrument and massspectra were acquired on a Bruker Daltonics Esquire 3000 instrumentusing electrospray ionization.

Example 1 Synthesis of Maytansinoid 4b

4-Mercapto-4-methylpentanoic acid (7): A 500 mL flask was equipped witha stir bar and a 150 mL addition funnel. The system was placed under anargon atmosphere. 150 mL of anhydrous tetrahydrofurane (THF) and 75 mLof 2.5 M n-BuLi in hexanes (18.7 mmol) were added via a canula and thesolution was cooled in a −78° C. dry ice/acetone bath. Acetonitrile (7.3g, 9.4 mL, 18 mmol) was added drop-wise via a syringe over approximately5 min. The reaction was stirred for 30 min, while whitelithium-acetonitrile precipitate was formed. Isobutylene sulfide (15 g,17 mmol) was dissolved in 100 mL of anhydrous THF and added drop wiseover approximately 30 min via the addition funnel. The cooling bath wasremoved and the reaction was allowed to stir for 3 hours. The flask wascooled in an ice/water bath as 38 mL of 0.5 M HCl was added drop-wise.The THF layer was retained and the aqueous layer was washed twice with75 mL of ethyl acetate. The THF and ethyl acetate layers were combined,dried over approximately 20 g of anhydrous sodium sulfate andtransferred to a 250 mL flask. Solvent was removed by rotary evaporationunder vacuum to give crude 6. Ethanol (30 mL) and a stir bar were added.The contents were stirred as a solution of 8.0 g NaOH in 30 mL deionizedwater was slowly added. The flask was equipped with a reflux condenserand placed under an argon atmosphere. The reaction was refluxedovernight then cooled to room temperature. Deionized water (60 mL) wasadded and the mixture was extracted twice with 25 mL portions of a 2:1mixture of ethyl acetate and hexane. The aqueous layer was acidified topH 2 with concentrated HCl then extracted three times with 75 mLportions of ethyl acetate. The organic layers were dried over anhydrousNa₂SO₄ and solvent was removed by rotary evaporation under vacuum togive 10 g of product 7 (39% yield). Material was used without furtherpurification. ¹H NMR (CDCl₃): δ1.38 (6H, s), 1.87-1.93 (2H, m), 2.08(1H, s), 2.51-2.57 (2H, m).

4-Methyl-4-(methyldithio)pentanoic acid (8): A solution ofmercaptopentanoic acid 7 (6.0 mL, 40 mmol) was dissolved in 50 mL ofdeionized water in a 250 mL flask. The solution was magnetically stirredas sodium carbonate (6.4 g, 60 mmol) was added to the acid at a ratethat would not cause excessive frothing. The flask was equipped with a100 mL addition funnel, which was charged with a solution of methylmethanethiolsulfonate (7.5 g, 60 mmol) dissolved in 30 mL ofglass-distilled 100% ethanol. The flask was cooled in an ice/water bathand the system was maintained under an argon atmosphere. The methylmethanethiolsulfonate solution was added drop-wise to the flask asrapidly as possible but without causing excessive frothing. The coolingbath was removed and the reaction mixture was allowed to stir for anadditional 3 hours. Solvent was removed by rotary evaporation undervacuum, until approximately 20 mL remained. After which 10 mL ofsaturated sodium bicarbonate and 30 mL of deionized water were added.The mixture was washed three times with 25 mL portions of ethyl acetatein a separatory funnel. The aqueous layer was adjusted to approximatelypH 2 with 5 M HCl and was extracted twice with 120 mL portions of ethylacetate. The organic layers were combined and washed with 20 mL of asolution composed of saturated NaCl and 1M HCl at a ratio of 4:1. Theorganic layer was then dried over 14 g of anhydrous sodium sulfate andsolvent was removed by rotary evaporation under vacuum to give 5.4 g ofproduct 8 (70% yield). The material can be taken to the next stepwithout further purification. ¹H NMR (CDCl₃): δ1.54 (6H, s), 2.15-2.21(2H, m), 2.64 (3H, s), 2.69-2.72 (2H, m). MS (M+Na⁺) calc.: 217.0,found: 217.1

N-Hydroxysuccinimidyl 4-methyl-4-(methyldithio)pentanoate (9):Methyldithiopentanoic acid 8 (3.0 g, 15 mmol) was dissolved in 20 mL ofmethylene chloride and stirred magnetically as N-hydroxysuccinimide(2.65 g, 23 mmol) was added followed by1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC, 4.4g, 23 mmol). The mixture was stirred under an argon atmosphere for 2hours. The reaction mixture was poured into a 125 mL separatory funnel,40 mL of ethyl acetate was added and the solution was washed twice with20 mL portions of 50 mM potassium phosphate buffer, pH 6.0, and oncewith 12 mL of saturated sodium chloride. The organic layer was driedover 14 g of anhydrous Na₂SO₄ and solvent was removed by rotaryevaporation under vacuum to give 4.0 g of product 9 (90% yield), whichwas used without further purification. ¹H NMR (CDCl₃): δ1.30 (6H, s),2.00-2.05 (2H, m), 2.39 (3H, s), 2.68-2.72 (2H, m), 2.73-2.83 (4H, m).MS (M+Na⁺) calc.: 314.0, found: 314.1

N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-L-alanine (10):N-Methyl-L-alanine (2.85 g, 18.0 mmol) was dissolved in 50 mL of a 1:1solution of dimethoxyethane and deionized water in a 125 mL flaskequipped with a magnetic stir bar. Triethylamine (6.9 g, 36 mmol) wasadded and the solution was vigorously stirred as 9 (5.44 g, 18 mmol)dissolved in 40 mL of the same solvent mixture was added drop-wise overapproximately 5 min. After 2 hours the reaction mixture was concentratedto approximately 40 mL by rotary evaporation under vacuum, then 10 mL ofdeionized water and 1 M HCl were added to give a pH of approximately 2.The mixture was poured into a separatory funnel and extracted twice with50 mL portions of ethyl acetate. The organic layers were combined andthen washed with 7 mL of saturated sodium chloride solution. The organiclayer was dried over 8.0 g of anhydrous Na₂SO₄ and the solvent wasremoved by rotary evaporation under vacuum. The residue was taken up ina minimum volume of ethyl acetate and purified by chromatography onsilica (silica: 40 micron flash grade, silica bed: 24×3.0 cm, mobilephase: hexanes:ethyl acetate: acetic acid 50:48:2). Fractions containingdesired product were combined and solvent was removed under vacuum.Residual acetic acid was removed by dissolving the residue in a minimumvolume of ethyl acetate and precipitating product by the rapid butdrop-wise addition of hexane with stirring. Hexane was added untilproduct was no longer detected in the supernatant by TLC analysis. Theprecipitate was vacuum dried for 4 hours to give 2.2 g of product 10(51% yield). ¹H NMR (CDCl₃): δ1.32 (6H, s), 1.42 (3H, d, J=7 Hz),1.90-97 (2H, m), 2.40 (3H, s), 2.42-2.49 (2H, m), 2.9 (3H, s), 5.15 (1H,q, J=7 Hz). MS (M+Na⁺) calc.: 302.1, found: 302.0.

N^(2′)-deacetyl-N^(2′)-(4-methyl-4-methyldithio-1-oxopentyl)maytansine(L-DM4-SMe, 4e). A solution of maytansinol (11, 25 mg, 0.44 mmol) andN-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-L-alanine (10, 42.0 mg,0.177 mmol) in 3 mL dichloromethane was magnetically stirred under anargon atmosphere as a solution of dicyclohexylcarbodiimide (DCC, 57.1mg, 0.277 mmol) in 0.67 mL dichloromethane was added. After 1 min asolution of 1 M ZnCl₂ in diethyl ether (0.03 mL, 0.03 mmol) was added.The mixture was stirred at room temperature for 2 hours then 5 mL ofethyl acetate was added and the mixture was vacuum filtered throughcourse filter paper. The filtrate was washed with 2 mL of saturatedsodium bicarbonate solution followed by 1 mL of saturated sodiumchloride solution. The organic layer was dried over 2 g of anhydroussodium sulfate. And solvent was removed under vacuum and the residue waspurified by silica chromatography using a mixture of dichloromethane andmethanol to remove unreacted maytansinol. Fractions containing desiredproduct were combined and solvent was removed under vacuum to give amixture of diastereomers 4e and 4f. The residue was taken up in aminimum volume of ethyl acetate and purified on a 50 cm by 250 cm, 10micron Diazem™ CN column using as mobile phase a mixture of hexane,2-propanol and ethyl acetate at a ratio of 68:8:24. The flow rate was118 mL/min. Under these conditions the desired product 4e eluted with aretention time of 11 min and the undesired diastereomer 4f had aretention time of 19 min. Fractions containing desired product werecombined and solvent was removed under vacuum to give 12.0 mg of product4e (36% yield). ¹H NMR (CDCl₃): δ0.80 (3H, s), 1.28-1.36 (13H, m),1.42-1.46 (2H, m), 1.53-1.63 (2H, m), 1.64 (3H, s), 1.75-1.85 (1H, m),1.90-2.10 (1H, m), 2.18 (1H, dd, J=3 Hz and 14 Hz), 2.31 (3H, s),2.40-2.49 (1H, m), 2.50-2.65 (1H, m), 2.85 (3H, s), 3.04 (1H, d, J=9Hz), 3.11 (1H, d, J=11 Hz), 3.23 (3H, s), 3.35 (3H, s), 3.49 (1H, d, J=9Hz), 3.63 (1H, d, J=12 Hz), 3.98 (3H, s), 4.27 (1H, t, J=10 Hz), 4.79(1H, dd, J=3 Hz and 12 Hz), 5.41 (1H, q, J=7 Hz), 5.66 (1H, dd J=9 Hzand 15 Hz), 6.21 (1H, s), 6.42 (1H, dd, J=11 Hz and 15 Hz), 6.65 (1H, d,J=1.5 Hz), 6.73 (1H, d, J=11 Hz), 6.81 (1H, d, J=1.5 Hz). Highresolution MS (M+H⁺) calc.: 826.3174, found: 826.3150.

N^(2′)-deacetyl-N^(2′)-(4-mercapto-4-methyl-1-oxopentyl)maytansine(L-DM4, 4b). The disulfide 4e from above (12 mg, 0.015 mmol) wasdissolved in 1.0 mL of 1:1 ethyl acetate:methanol. A solution ofdithiothreitol (18 mg, 0.117 mmol) in 0.50 mL of 50 mM phosphate buffer,pH 7.5, was then added. The solution was magnetically stirred under anargon atmosphere for 3 hours, then 1 mL of 200 mM phosphate buffer, pH6.0, was added and the mixture was extracted three times with 2 mLportions of ethyl acetate. The organic layers were combined and washedwith 1 mL of saturated sodium chloride solution, then dried over 1 g ofanhydrous sodium sulfate. The solvent was removed under vacuum and theresidue was taken up in a minimum of ethyl acetate and purified on a 50cm×250 cm, 10 micron Diazem™ CN column using as mobile phase a mixtureof hexane, 2-propanol and ethyl acetate at a ratio of 70:8:22. The flowrate was 22 mL/min. The desired product 4b eluted with a retention timeof 10 min. Fractions containing pure 4b were combined and the solventwas removed under vacuum to give 11 mg of 4b (97% yield). ¹H NMR(CDCl₃): δ0.80 (3H, s), 1.19-1.23 (1H, m), 1.28-1.36 (12H, m), 1.42-1.46(2H, m), 1.53-1.63 (2H, m), 1.64 (3H, s), 1.75-1.85 (1H, m), 1.90-2.10(1H, m), 2.18 (1H, dd, J=3 Hz and 14 Hz), 2.40-2.49 (1H, m), 2.50-2.65(2H, m), 2.88 (3H, s), 3.04 (1H, d, J=9 Hz), 3.11 (1H, d, J=11 Hz), 3.23(3H, s), 3.35 (3H, s), 3.49 (1H, d, J=9 Hz), 3.63 (1H, d, J=12 Hz), 3.98(3H, s), 4.27 (1H, t, J=10 Hz), 4.79 (1H, dd, J=3 Hz and 12 Hz), 5.41(1H, q, J=7 Hz), 5.66 (1H, dd J=9 Hz and 15 Hz), 6.21 (1H, s), 6.42 (1H,dd, J=11 Hz and 15 Hz), 6.65 (1H, d, J=1.5 Hz), 6.73 (1H, d, J=11 Hz),6.81 (1H, d, J=1.5 Hz). High resolution MS (M+Na⁺) calc.: 802.3101,found: 802.3116.

Example 2 Synthesis of Maytansinoid 4a

4-Methyldithio-pentanoic acid (13): A solution of 4-mercaptopentanoicacid (12, 16.6 g, 124 mmol) was dissolved in 350 mL of deionized waterin a 500 mL flask. The solution was magnetically stirred as sodiumcarbonate (19.7 g, 186 mmol) was added to the acid at a rate that wouldnot cause excessive frothing. The flask was equipped with a 250 mLaddition funnel, which was charged with a solution of methylmethanethiolsulfonate (23.4 g, 186 mmol) dissolved in 220 mL ofglass-distilled 100% ethanol. The flask was cooled in an ice/water bathand the system was maintained under an argon atmosphere. The methylmethanethiolsulfonate solution was added drop-wise to the flask asrapidly as possible but at such a speed as to prevent excessivefrothing. The cooling bath was removed and the reaction mixture wasallowed to stir for an additional 2 hours. Solvent was removed by rotaryevaporation under vacuum, until approximately 250 mL remained. Afterwhich 30 mL of saturated sodium bicarbonate solution and 50 mL ofdeionized water were added. The mixture was washed three times with 200mL portions of ethyl acetate in a separatory funnel. The aqueous layerwas adjusted to approximately pH 2 with 5 M HCl and was extracted twicewith 400 mL portions of ethyl acetate. The organic layers were combined,then washed with 60 mL of a 4:1 mixture of saturated NaCl solution and1M HCl, then dried over 50 g of anhydrous sodium sulfate, and finally,the solvent was removed by rotary evaporation under vacuum to give 10.2g of product 13 (45% yield). The material was used in the next reactionwithout further purification. H¹ NMR δ1.36 (3H, d, J=7 Hz), 1.84-1.95(H, m), 1.85-2.56 (1H, m), 2.42 (3H, s), 2.53 (2H, t, J=7 Hz), 2.85-2.95(1H, m), MS (M+Na⁺) calc.: 203.3, found: 203.2.

N-Hydroxysuccinimidyl 4-methyldithio-pentanoate (14):4-methyldithio-pentanoic acid (13, 0.75 g, 4.16 mmol) was dissolved in7.0 mL of methylene chloride and stirred magnetically whileN-hydroxysuccinimide (0.526 g, 4.57 mmol) was added followed by1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.877 g,4.57 mmol). The mixture was stirred under an argon atmosphere for 2.5hours, then poured into a 60 mL separatory funnel containing 20 mL ofethyl acetate. The resulting solution was washed twice with 15 mLportions of 50 mM potassium phosphate buffer, pH 6.0, and once with 5 mLof saturated sodium chloride. The organic layer was dried over 8 g ofanhydrous Na₂SO₄ and the solvent was removed by rotary evaporation undervacuum to give 1.15 g of product 14 (87% yield), which was used for thenext reaction without further purification. H¹ NMR δ1.48 (3H, d, J=7),2.06 (1H, m), 2.17 (1H, m), 2.55 (3H, s), 2.93 (2H, t, J=7), 2.98 (4H,s), 3.15 (1H, m). MS (M+Na⁺) calc.: 304.1, found: 304.0.

N-methyl-N-(4-methyldithio-1-oxopentyl)-L-alanine (15):N-Methyl-L-alanine (0.64 g, 6.2 mmol) was dissolved in 8 mL of a 1:1mixture of dimethoxyethane and deionized water in a 125 mL flaskequipped with a magnetic stir bar. Triethylamine (0.841 g, 8.3 mmol) wasadded and the flask was vigorously stirred as a solution of 14 (1.0 g,3.6 mmol) in 8 mL of the same solvent mixture was added drop-wise overapproximately 5 min. After 2 hours, the reaction mixture wasconcentrated to approximately 3 mL by rotary evaporation under vacuum,then 15 mL of deionized water and 1 M HCl were added to give a pH ofapproximately 2. The mixture was poured into a 60 mL separatory funneland extracted twice with 15 mL portions of ethyl acetate. The organiclayers were combined, washed with 3 mL of saturated sodium chloridesolution, then dried over 8.0 g of anhydrous Na₂SO₄, and finally, thesolvent was removed by rotary evaporation under vacuum. The residue wastaken up in a minimum volume of ethyl acetate and purified by silicachromatography (silica: 40 micron flash grade, silica bed 24×3.0 cm,mobile phase hexanes:ethyl acetate:acetic acid 50:48:2). Fractionscontaining desired product 15 were combined and the solvent was removedunder vacuum. Residual acetic acid was removed by dissolving the residuein a minimum volume of ethyl acetate and precipitating product by therapid but drop-wise addition of hexane with stirring. Hexane was addeduntil product was no longer detected in the supernatant by TLC analysis.The precipitate was vacuum dried to give 0.60 g of product 15 (62%yield). H¹ NMR δ1.35 (3H, d, J=7), 1.41 (3H, d, J=7), 1.94-2.03 (2H, m),2.43 (3H, s), 2.50-2.55 (2H, m), 2.83-2.93 (1H, m), 2.98 (3H, s), 5.14(1H, q, J=7). MS (M+Na⁺) calc.: 288.1, found: 288.1.

N^(2′)-deacetyl-N^(2′)-(4-methyldithio-1-oxopentyl)maytansine(L-DM3-SMe, 4c): A solution of Maytansinol (25 mg, 0.44 mmol) and 15(42.0, 0.177 mmol) in 3 mL dichloromethane was magnetically stirredunder an argon atmosphere as a solution of dicyclohexylcarbodiimide(DCC, 57.1 mg, 0.277 mmol) in 0.67 mL dichloromethane was added. After 1min, a solution of 1 M ZnCl₂ in diethyl ether (0.03 mL, 0.03 mmol) wasadded. The mixture was stirred at room temperature for 2 hours, then 5mL of ethyl acetate was added and the mixture was vacuum filteredthrough course filter paper. The filtrate was washed with 2 mL ofsaturated sodium bicarbonate solution followed by 1 mL of saturatedsodium chloride solution. The organic layer was dried over 2 g ofanhydrous sodium sulfate, then the solvent was removed under vacuum. Theresidue was purified by silica chromatography using a mixture ofdichloromethane and methanol to remove unreacted maytansinol. Fractionscontaining desired product were combined and solvent was removed undervacuum to give a mixture of the diastereomers 4c and 4d. The residue wastaken up in a minimum volume of ethyl acetate and purified on a 50 cm by250 cm, 10 micron Diazem™ CN column using as mobile phase a 68:8:24mixture of hexane, 2-propanol and ethyl acetate. The flow rate was 118mL/min. The desired product 4c eluted with a retention time of 11 min,the undesired diastereomer 4d had a retention time of 19 min. Fractionscontaining the desired product were combined and stripped of the solventunder vacuum to give 12.0 mg of product 4c (36% yield). ¹H NMR (CDCl₃):δ0.80 (3H, s), 1.19-1.23 (1H, m), 1.28-1.36 (9H, m), 1.42-1.46 (1H, m),1.53-1.63 (2H, m), 1.64 (3H, s), 1.80-1.89 (1H, m), 1.90-2.09 (1H, m),2.18 (1H, dd, J=3 Hz and 14 Hz), 2.32 (3H, s), 2.33-2.42 (1H, m),2.49-2.62 (2H, m), 2.88 (3H, s), 3.04 (1H, d, J=9 Hz), 3.11 (1H, d, J=11Hz), 3.23 (3H, s), 3.35 (3H, s), 3.49 (1H, d, J=9 Hz), 3.63 (1H, d, J=12Hz), 3.98 (3H, s), 4.27 (1H, t, J=10 Hz), 4.79 (1H, dd, J=3 Hz and 12Hz), 5.41 (1H, q, J=7 Hz), 5.66 (1H, dd J=9 Hz and 15 Hz), 6.21 (1H, s),6.42 (1H, dd, J=11 Hz and 15 Hz), 6.65 (1H, d, J=1.5 Hz), 6.73 (1H, d,J=11 Hz), 6.81 (1H, d, J=1.5 Hz). MS (M+Na⁺) calc.: 834.3, found: 834.3.

N^(2′)-deacetyl-N^(2′)-(4-mercapto-1-oxopentyl)maytansine (L-DM3, 4a):L-DM3-SMe (4c, 12 mg, 0.015 mmol) was dissolved in 1.0 mL of a 1:1mixture of ethyl acetate and methanol. A solution of dithiothreitol (18mg, 0.117 mmol) in 0.50 mL of 50 mM phosphate buffer, pH 7.5, was thenadded. The reaction solution was magnetically stirred under an argonatmosphere for 3 hours, then 1 mL of 200 mM phosphate buffer pH 6.0 wasadded and the mixture was extracted three times with 2 mL portions ofethyl acetate. The organic layers were combined and washed with 1 mL ofsaturated sodium chloride solution, then dried over 1 g of anhydroussodium sulfate. Solvent was removed under vacuum and the residue wastaken up in a minimum of ethyl acetate and purified on a 50 cm×250 cm,10 micron Diazem™ CN column using as mobile phase a 70:8:22 mixture ofhexane, 2-propanol and ethyl acetate. The flow rate was 22 mL/min. Thedesired product eluted with a retention time of 10 min. Fractionscontaining pure product were combined and the solvent was removed undervacuum to give 11 mg of product 4a (97% yield). ¹H NMR (CDCl₃): δ0.80(3H, s), 1.19-1.23 (1H, m), 1.28-1.36 (9H, m), 1.42-1.46 (1H, m),1.53-1.63 (2H, m), 1.64 (3H, s), 1.80-1.89 (1H, m), 1.90-2.09 (1H, m),2.18 (1H, dd, J=3 Hz and 14 Hz), 2.33-2.42 (1H, m), 2.49-2.62 (2H, m),2.88 (3H, s), 3.04 (1H, d, J=9 Hz), 3.11 (1H, d, J=11 Hz), 3.23 (3H, s),3.35 (3H, s), 3.49 (1H, d, J=9 Hz), 3.63 (1H, d, J=12 Hz), 3.98 (3H, s),4.27 (1H, t, J=10 Hz), 4.79 (1H, dd, J=3 Hz and 12 Hz), 5.41 (1H, q, J=7Hz), 5.66 (1H, dd J=9 Hz and 15 Hz), 6.21 (1H, s), 6.42 (1H, dd, J=11 Hzand 15 Hz), 6.65 (1H, d, J=1.5 Hz), 6.73 (1H, d, J=11 Hz), 6.81 (1H, d,J=1.5 Hz). MS: (M+Na⁺) calc.: 788.3, found: 788.3.

Example 3 Synthesis of Maytansinoid 4g,h (FIG. 3 c)

R-1,3-Di-O-p-toluenesulfonyl-butane (17): A solution ofR-(−)-1,3-butanediol (16, 2.00 g, 22.22 mmol) in a mixture of drypyridine (40 mL) and dry toluene (60 mL), was treated withp-toluenesulfonyl chloride (12.70 g, 66.84 mmol) under argon at 0° C.After stirring at 0° C. for 5 min. followed by stirring at roomtemperature for 2 h, the mixture was evaporated under vacuum,redissolved in ethyl acetate, and washed with 0.1 M aqueous NaHCO₃,followed by saturated NaCl. The organic layer was dried over MgSO₄,filtered, and the solvent was evaporated. Purification by chromatographyon silica gel, eluting with 1:2 (v/v) ethyl acetate/hexane gave 6.51 g(74%) of the title product 17. R_(f)=0.40 (1:1 EtOAc/hexane); ¹H NMR(CDCl₃) 7.76 (dd, 4H, J=1.0, 8.0 Hz), 7.35 (dt, 4H, J=0.4, 8.0+8.0 Hz),4.70 (m, 1H), 4.03 (m, 1H), 3.94 (m, 1H), 2.46 (s, 6H), 1.92 (m, 2H),1.26 (d, 3H, J=6.3 Hz); ¹³C NMR 145.17, 133.00, 130.11, 128.12, 127.91,76.28, 66.21, 36.08, 21.86, 21.06; MS: 420.99 (M+Na)⁺, 421.93 (M+1+Na)⁺.

S-4-O-Ethylxanthic-pentanenitrile (18): A solution ofR-1,3-di-O-p-toluenesulfonyl-butane (17, 4.80 g, 12.06 mmol) in dry DMSO(50 mL) was treated with NaCN (0.65). After stirring at RT under argonfor 18 h, the reaction mixture was diluted with ethyl acetate, washedsuccessively with cold 1.0 M of NaH₂PO₄ pH 7.5, water and 1.0 M ofNaH₂PO₄ pH 4.0. The organic layer was separated and dried over MgSO₄,filtered, and then evaporated to give 2.63 g crude ofR-3-O-p-toluenesulfonyl-pentanenitrile. MS 275.80 (M+Na)⁺, 276.75(M+1+Na)⁺. The product was used directly without further purification.

To the solution of crude of R-3-O-p-toluenesulfonyl-pentanenitrile (2.63g) in ethanol (15 mL) was added potassium O-ethylxanthate (4.55 g) inethanol (50 mL). After stirring overnight under argon, the mixture wasconcentrated, diluted with ethyl acetate, and filtered through a shortsilica column. The eluant was concentrated and purified bychromatography on silica gel, eluting with 1:4 (v/v) EtOAc/hexane, togive 1.54 g (63%, 2 steps) of the title product 18. R_(f)=0.40 (1:4EtAc/hexane). ¹H NMR (CDCl₃) 4.67 (dd, 2H, J=7.1, 14.2 Hz), 3.86 (ddd,1H, J=7.0, 14.0, 21.9 Hz), 2.50 (t, 2H J=7.3+7.6 Hz), 2.06 (m, 2H), 1.44(m, 6H); ¹³C NMR 213.04, 119.16, 70.28, 44.57, 32.10, 20.20, 15.21,13.93; MS: 226.51 (M+Na)⁺, 242.51 (M+K)⁺.

S-(+)-4-Methyldithio-pentanoic acid (19): To a solution ofS-4-O-Ethylxanthic-pentanenitrile (18, 1.95 g (9.61 mmol) in a mixtureof ethanol (10 mL) and water (150 mL) was added 5.0 g of NaOH. Thereaction mixture was refluxed overnight under argon. The mixture wascooled to room temperature and diluted with water (150 ml) and extractedwith 1:1 EtOAc/hexane (2×100 ml). The aqueous layer was acidified withH₃PO₄ to pH 2.5˜3.0 and extracted with EtOAc (6×75 ml). The organiclayers were combined, dried over MgSO₄, filtered and evaporated todryness to give the crude S-4-mercaptopentanoic acid. This crude productwas used directly for next step without further purification.

To a solution of crude S-4-mercaptopentanoic acid (1.2 g) in a mixtureof ethanol (50 mL) and 0.5 M NaH₂PO₃, pH 7.0 (75 mL), was added dropwisemethyl methanethiolsulfonate (1.47 g, 11.65 mmol) in 5 dry THF (5 mL)over 45 min at 0° C. After stirring under argon at 0° C. for 30 min,followed by stirring at room temperature for 2 h, the mixture wasconcentrated and extracted with dichloromethane (2×50 ml). The aqueouslayer was acidified with H₃PO₄ to pH 2.5˜3.0 and extracted with EtOAc(4×100 ml). The organic layers were combined, dried over MgSO₄, filteredand evaporated. The residue was purified by chromatography over silicagel, eluting with (1:100:400 HOAc/EtOAc/hexane) to give 1.43 g (83%) ofthe title product 19. R_(f)=0.32 (1:100:400 HOAc/EtAc/hexane); ¹H NMR(CDCl₃) 2.91 (ddd, 1H, J=6.8, 13.7, 20.5 Hz), 2.53 (t, 2H, J=7.7+7.4Hz), 2.42 (s, 3H), 1.94 (m, 2H), 1.36 (d, 3H, J=6.8 Hz); ¹³C NMR 179.18,45.35, 31.58, 30.73, 24.70, 21.05; MS: 202.92 (M+Na)⁺, 203.91 (M+1+Na)⁺;[α]=41.35 (c=2, CH₃OH).

N-methyl-N-[4-(S)-methyldithio-1-oxopentyl[-S-alanine (15a):S-(+)-4-(Methyldithio)-pentanoic acid (19) was converted into theN-hydroxysuccinimdyl ester 20, by the method described above forcompound 14. Reaction with N-methyl-L-alanine by the procedure describedabove for compound 15 gave 15a, (62% yield). H¹ NMR δ1.36 (3H, d, J=7),1.42 (3H, d, J=7), 1.93-1.98 (2H, m), 2.40 (3H, s), 2.50-2.53 (2H, m),2.90-2.95 (1H, m), 2.99 (3H, s), 5.14 (1H, q, J=7), MS: (M+Na) calc.:288.1, found: 288.1

N^(2′)-deacetyl-N^(2′)-(4-(S)-methyldithio-1-oxopentyl)maytansine(DM3-SMe, 4g,h): Maytansinol (11) was coupled with 15a, using DCC andzinc chloride in dichloromethane, as described above for the synthesisof 4c. A mixture of 2 diastereomers bearing the N-methyl-S-alanyl moiety(4g, S,S) and the N-methyl-R-alanyl moiety (4h, R,S) were obtained. Thediastereomers were separated by HPLC on a Kromasil cyano column (4.6mm×250 mm), using an isocratic elution at a flow rate of 1 mL/min, withhexane:ethyl acetate:2-propanol (68:24:8, v/v/v). Under theseconditions, the isomer 4g (S.S) eluted at 24.5 min. Mass spectrum: m/z834.2 (M+Na)⁺. The peak for the other isomer 4h (R,S) was well separatedand eluted at 34.6 min. MS: m/z 834.2 (M+Na)⁺.

Example 4 Synthesis of Maytansinoid 4k,l (FIG. 3 d)

S-1,3-Di-O-p-toluenesulfonyl-butane 22: A solution ofS-(−)-1,3-butanediol (21, 2.00 g (22.22 mmol) in a mixture of drypyridine (40 mL) and dry toluene (60 mL) was treated withp-toluenesulfonyl chloride (12.70 g, 66.84 mmol) under argon at 0° C.After stirring at 0° C. for 5 min. followed by stirring at roomtemperature for 2 h, the mixture was evaporated under vacuum. Theresidue was redissolved in ethyl acetate, washed with 0.1 M aqueousNaHCO₃, and saturated NaCl. The organic layer was separated, dried overMgSO₄, filtered and evaporated. The residue was purified bychromatography over silica gel, eluting with 1:2 ethyl acetate/hexane togive 6.25 g (71%) of the title product 22 R_(f)=0.40 (1:1 EtOAc/hexane);¹H NMR (CDCl₃) 7.76 (dd, 4H, J=1.0, 8.0 Hz), 7.35 (dt, 4H, J=0.4,8.0+8.0 Hz), 4.70 (m, 1H), 4.03 (m, 1H), 3.94 (m, 1H), 2.46 (s, 6H),1.92 (m, 2H), 1.26 (d, 3H, J=6.3 Hz); ¹³C NMR 145.17, 133.00, 130.11,128.12, 127.91, 76.28, 66.21, 36.08, 21.86, 21.06; MS: 420.99 (M+Na)⁺.

R-4-O-Ethylxanthic-pentanenitrile (23): A solution ofS-1,3-di-O-p-toluenesulfonyl-butane (22, 6.25 g (15.70 mmol) in 60 dryDMSO (50 mL) was treated with NaCN (0.85 g). The reaction mixture wasstirred under argon for 18 h at RT. The reaction mixture was thendiluted with ethyl acetate, washed sequentially with cold 1.0 M ofNaH₂PO₄ pH 7.5, water and 1.0 M of NaH₂PO₄ pH 4.0. The organic layer wasdried over MgSO₄, filtered, evaporated to give 3.62 g crude ofS-3-O-p-toluenesulfonyl-pentanenitrile. The product was used directlywithout further purification.

To a solution of crude S-3-O-p-toluenesulfonyl-pentanenitrile (3.62 g)in ethanol (50 mL), was added potassium O-ethylxanthate (5.72 g) inethanol (100 mL). After stirring under argon overnight, the mixture wasconcentrated, diluted with ethyl acetate and filtered through a shortcolumn of silica gel. The eluant was concentrated, and the residue waspurified by chromatography over silica gel, eluting with 1:4EtOAc/hexane to give 2.0 g (62%, 2 steps) of the title product 23.R_(f)=0.40 (1:4 EtAc/hexane). ¹H NMR (CDCl₃) 4.67 (dd, 2H, J=7.1, 14.2Hz), 3.86 (ddd, 1H, J=7.0, 14.0, 21.9 Hz), 2.50 (t, 2H J=7.3+7.6 Hz),2.06 (m, 2H), 1.44 (m, 6H); ¹³C NMR 213.04, 119.16, 70.28, 44.57, 32.10,20.20, 15.21, 13.93; MS: 226.51 (M+Na)⁺, 242.51 (M+K)⁺.

R-(−)-4-Methyldithio-pentanoic acid (24): A solution ofR-4-O-Ethylxanthic-pentanenitrile (23, 2.0 g, 9.85 mmol) in a mixture ofethanol (10 mL) and 200 ml of water was treated with NaOH (6.0 g). Thereaction mixture was refluxed overnight under argon. The mixture wasdiluted with water (150 ml) and extracted with 1:1 EtOAc/hexane (2×100ml). The aqueous layer was acidified with H₃PO₄ to pH 2.5˜3.0 andextracted with EtAc (6×75 ml). The organic layers were combined, driedover MgSO₄, filtered and evaporated to dryness to give the crudeR-4-mercaptopentanoic acid. This crude product was used directly fornext step without further purification.

To a solution of 1.60 g of the crude R-4-mercaptopentanoic acid in amixture of ethanol (50 mL) and 0.5 M NaH₂PO₄, pH 7.0 (75 mL) was addeddropwise methyl methanethiolsulfonate (1.96 g, 15.53 mmol) in dry THF (7mL) over 45 min at 0° C. The reaction mixture was stirred under argon at0° C. for 30 min and then at room temperature for 2 h. The mixture wasconcentrated and extracted with dichloromethane (2×50 ml). The aqueouslayer was acidified with H₃PO₄ to pH 2.5˜3.0 and extracted with EtOAc(4×100 ml). The organic layers were combined, dried over MgSO₄, filteredand evaporated. The residue was purified by chromatography over silicagel, eluting with 1:100:400 HOAc/EtOAc/hexane to give 1.65 g (93%) ofthe title product 24. R_(f)=0.32 (1:100:400 HOAc/EtOAc/hexane); ¹H NMR(CDCl₃) 2.91 (ddd, 1H, J=6.8, 13.7, 20.4 Hz), 2.53 (t, 2H, J=7.7+7.4Hz), 2.42 (s, 3H), 1.96 (m, 2H), 1.36 (d, 3H, J=6.8 Hz); ¹³C NMR 179.46,45.67, 31.91, 31.07, 25.02, 21.36; MS: 202.9 (M+Na)⁺, 203.9 (M+1+Na)⁺;[α]=−39.16 (c=2, CH₃OH).

N-methyl-N-[4-(R)-methyldithio-1-oxopentyl]-S-alanine (15b):R-(+)-4-Methyldithio-pentanoic acid (24) was converted into theN-hydroxysuccinimdyl ester 25, by the method described above forcompound 14. Reaction with N-methyl-L-alanine by the procedure describedabove for compound 15 gave 15b. MS: m/z (M+Na): calc.: 288.1, found:288.1

N^(2′)-deacetyl-N^(2′)-(4-(R)-methyldithio-1-oxopentyl)maytansine(DM3-SMe, 4k,l): Maytansinol (11) was coupled with 15b, using DCC andzinc chloride in dichloromethane, as described above for the synthesisof 4c. A mixture of 2 diastereomers bearing the N-methyl-S-alanyl moiety(4k, S,R) and the N-methyl-R-alanyl moiety (4l, R,R) were obtained. Thediastereomers were separated by HPLC on a Kromasil cyano column (4.6mm×250 mm), using an isocratic elution at a flow rate of 1 mL/min, withhexane:ethyl acetate:2-propanol (68:24:8, v/v/v). Under theseconditions, the isomer 4k (S.R) eluted at 23.9 min. Mass spectrum: m/z834.2 (M+Na)⁺. The peak for the other isomer 41 (R,R) was well separatedand eluted at 33.7 min. MS: m/z 834.2 (M+Na)⁺.

Example 5a In Vitro Cytotoxicity of Maytansinoids andAntibody-Maytansinoid Conjugates

The KB (ATCC CCl-17) cell line is of human epithelial origin. TheSK-BR-3 (ATCC HTB-30) cell line was established from a human breastadenocarcinoma. The human colon tumor cell lines COLO 205 (ATCC CCL-222)and HT-29 (ATCC HTB 38), the human melanoma cell line A-375 (ATCC CRL1619), the human Burkitts lymphoma cell line Ramos (ATCC CRL-1596) andthe human myeloid leukemia cell line HL-60 (ATCC CCL-240) were allobtained from ATCC, Maryland. Cell lines were grown in Dulbecco'smodified Eagles Medium (DMEM, Biowhittaker, Walkersville, Md.) withL-glutamine supplemented with 10% fetal bovine serum (Hyclone, Logan,Utah) and 50 μg/mL gentamycin sulfate (Life Technologies, Rockville,Md.). Cells were maintained at 36-37.5° C. in a humidified atmospherethat contained 6% CO₂.

The cytotoxicity study performed used a clonogenic assay. The test celllines were plated into 6-well culture dishes at a constant number of1000 cells per well. Cells were incubated with varying concentrations (0to 3 nM) of the various maytansinoids (free or conjugated to antibodies)for 72 hours. The medium was then aspirated from the plates and replacedwith fresh medium. Cultures were allowed to grow, and form colonies, fora total of 7-10 days after plating. The cultures were then fixed andstained with 0.2% crystal violet in 10% formalin/PBS and colonies werecounted. Plating efficiency of non-treated cells (medium alone) wasdetermined by dividing the number of colonies counted by the number ofcells plated. Surviving fraction of cells exposed to the drugs wasdetermined by dividing the number of colonies in wells that were exposedto the drug by the number of colonies in the control wells.

The results of the in vitro cytotoxicity measurements of the newmaytansinoids of the present invention are shown in FIG. 4. The newmaytansinoids 4c,e bearing hindered disulfide bonds are highly cytotoxictowards both cell lines tested, SK-BR-3 and A-375, with IC₅₀ valuesranging from 7×10⁻¹² M to 2.5×10⁻¹¹ M. Thus, incorporation of alkylsubstituents on the carbon bearing the disulfide moiety has preservedhigh cytotoxic potency. The sterically hindered thiol-containingmaytansinoid 4a of the present invention is 30 to 50-fold more potentthan the previously described corresponding unhindered maytansinoid 1.Thus, incorporation of alkyl substituents on the carbon atom bearing thethiol moiety greatly enhances potency.

The results of in vitro testing of antibody conjugates of themaytansinoids of the present invention are shown in FIGS. 4 c and 4 d.The linkage of the two new maytansinoids, 4a or 4b, to the huC242antibody directed against human colon tumors, resulted inantigen-specific killing of target cells. Thus, the conjugates arehighly potent towards antigen-positive COLO 205 cells, with IC₅₀ valuesranging from 1.1 to 1.3×10⁻¹¹M. In contrast, the conjugates are 100 to200-fold less cytotoxic towards antigen-negative A-375 cells,demonstrating that the new maytansinoids of the present inventionproduce conjugates that possess sterically hindered disulfide bonds, anddisplay high target specific cytotoxicity.

Example 5b Preparation of Cytotoxic Conjugates of huC242 Antibody UsingMaytansinoids 4a or 4b Method A, FIG. 5 a,b

A solution of huC242 antibody (8 mg/mL) in aqueous buffer (50 mMpotassium phosphate, 50 mM sodium chloride, 2 mMethylenediaminetetraacetic acid disodium salt), pH 6.5, was incubatedfor 2 h with a 7 to 10-fold molar excess of SPDP [succinimidyl3-(2-pyridyldithio)propionate, 3a), or withN-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB, 3b). The reactionmixture was purified by passage through a Sephadex G25 gel filtrationcolumn. The concentration of the antibody was determinedspectrophotometrically using the known extinction coefficients for theantibody ε_(280 nm)=217,560 M-1 cm-1.

The modified antibody was diluted to 2.5 mg/mL in aqueous buffer (50 mMpotassium phosphate, 50 mM sodium chloride, 2 mMethylenediaminetetraacetic acid disodium salt), pH 6.5, and then treatedwith a 1.5 to 2.5 molar excess of either DM3 or DM4 in dimethylacetamide(final concentration of DMA was 3% v/v). The reaction mixture wasincubated for 18 h at room temperature. The reaction mixture waspurified by passage through a Sephadex G25 gel filtration column. Theconcentration of the conjugate was determined spectrophotometricallyusing the known extinction coefficients for the antibodyε_(280 nm)=217,560 M⁻¹ cm⁻ and ε_(252 nm)=80,062 M⁻¹ cm⁻¹; for DM3 orDM4, ε_(280 nm)=5,700 M⁻¹ cm⁻¹ and ε_(252 nM)=26,790 M⁻¹ cm⁻¹). Theresulting conjugate was monomeric and contained, on the average, 3.2-3.5DM3 or DM4 molecules linked per antibody molecule.

Example 5c Preparation of Cytotoxic Conjugates of huC242 Antibody UsingMaytansinoids 4a or 4b Method B, FIG. 5 c

A solution of huC242 antibody (8 mg/mL) in aqueous buffer (50 mMpotassium phosphate, 50 mM sodium chloride, 2 mMethylenediaminetetraacetic acid disodium salt), pH 6.5, was incubatedfor 2 h with a 7 to 10-fold molar excess of SMCC [succinimidyl4-(N-maleimidomethyl)-cyclohexane-1-carboxylate, 26). The reactionmixture was purified by passage through a Sephadex G25 gel filtrationcolumn. The concentration of the antibody was determinedspectrophotometrically using the known extinction coefficients for theantibody ε_(280 nm)=217,560 M⁻¹ cm⁻¹.

The modified antibody was diluted to 2.5 mg/mL in aqueous buffer (50 mMpotassium phosphate, 50 mM sodium chloride, 2 mMethylenediaminetetraacetic acid disodium salt), pH 6.5, and then treatedwith a 1.5 to 2.5 molar excess of either DM3 or DM4 in dimethylacetamide(final concentration of DMA was 3% v/v). The reaction mixture wasincubated for 18 h at room temperature. The reaction mixture waspurified by passage through a Sephadex G25 gel filtration column. Theconcentration of the conjugate was determined spectrophotometricallyusing the known extinction coefficients (for the antibodyε_(280 nm)=217,560 M⁻¹ cm⁻ and ε_(252 nm)=80,062 M⁻¹ cm⁻¹; for DM3 orDM4, ε_(280 nm)=5,700 M⁻¹ cm⁻¹ and ε_(252 nM)=26,790 M⁻¹ cm⁻¹). Theresulting conjugate was monomeric and contained, on the average, 3.2-3.5DM3 or DM4 molecules linked per antibody molecule.

Example 5d Preparation of Cytotoxic Conjugates of huC242 Antibody UsingMaytansinoids 4a or 4b Method C, FIG. 5 d

A solution of huC242 antibody (8 mg/mL) in aqueous buffer (50 mMpotassium phosphate, 50 mM sodium chloride, 2 mMethylenediaminetetraacetic acid disodium salt), pH 6.5, was incubatedfor 2 h with a 7 to 10-fold molar excess of SIAB [N-succinimidyl(4-iodoacetyl)aminobenzoate, 27). The reaction mixture was purified bypassage through a Sephadex G25 gel filtration column. The concentrationof the antibody was determined spectrophotometrically using the knownextinction coefficients for the antibody ε_(280 nm)=217,560 M⁻¹ cm⁻¹.

Example 6 In Vivo Efficacy of huC242-Maytansinoid Conjugates AgainstHT-29 Xenografts

Five-week-old female SCID mice (20 animals) were inoculatedsubcutaneously in the right flank with HT-29 human colon carcinoma cells(1.5×10⁶ cells/mouse) in 0.1 mL of serum-free medium. The tumors weregrown for 11 days to an average size of 100 mm³. The animals were thenrandomly divided into four groups (5 animals per group). The first groupreceived huC242-DM1 conjugate (DM1 dose of 75 μg/kg, qd×5) administeredintravenously. The second group received huC242-DM3 conjugate (DM3 doseof 75 μg/kg, qd×5) administered intravenously. The third group receivedhuC242-DM4 conjugate (DM4 dose of 75 μg/kg, qd×5), while a fourth groupof animals served as controls and received PBS using the same treatmentschedule as in groups 1-3.

The sizes of the tumors were measured twice weekly and the tumor volumeswere calculated with the formula: tumor volume=½(length×width×height).The weight of the animals was also measured twice per week. The resultsare shown in FIG. 7. The tumors in the control group of mice grew to asize of nearly 1000 mm³ in 35 days. Treatment with huC242-DM1 resultedin a tumor growth delay of 18 days, while conjugates made with themaytansinoids 4a and 4b of the present invention were significantly moreefficacious and prolonged the tumor growth delay to 28 days and 36 days,respectively.

Example 7 In Vivo Efficacy of huC242-Maytansinoid Conjugates AgainstCOLO 205 Xenografts

Five-week-old female SCID mice (20 animals) were inoculatedsubcutaneously in the right flank with COLO 205 human colon carcinomacells (1.5×10⁶ cells/mouse) in 0.1 mL of serum-free medium. The tumorswere grown for 11 days to an average size of 100 mm³. The animals werethen randomly divided into four groups (5 animals per group). The firstgroup received huC242-DM1 conjugate (DM1 dose of 75 μg/kg, qd×5)administered intravenously. The second group received huC242-DM3conjugate (DM3 dose of 75 μg/kg, qd×5) administered intravenously. Thethird group received huC242-DM4 conjugate (DM4 dose of 75 μg/kg, qd×5),while a fourth group of animals served as controls and received PBSusing the same treatment schedule as in groups 1-3.

The sizes of the tumors were measured twice weekly and the tumor volumeswere calculated with the formula: tumor volume=½(length×width×height).The weight of the animals was also measured twice per week. The resultsare shown in FIG. 8. The tumors in the control group of mice grew to asize of nearly 900 mm³ in 24 days. Treatment with huC242-DM1 resulted ina tumor growth delay of 20 days, while the conjugate made with themaytansinoid 4a of the present invention was considerably moreefficacious and caused complete tumor regressions lasting 45 days.Treatment with the conjugate made with the maytansinoid 4b of thepresent invention was even more efficacious, resulting in cures of allthe treated animals.

Example 8 In Vivo Efficacy of MY9-6-Maytansinoid Conjugates AgainstHL-60 Xenografts

Five-week-old female SCID mice (20 animals) were inoculatedsubcutaneously in the right flank with HL-60 human myeloid leukemiacells (1.5×10⁶ cells/mouse) in 0.1 mL of serum-free medium. The tumorswere grown for 12 days to an average size of 100 mm³. The animals werethen randomly divided into four groups (5 animals per group). The firstgroup received MY9-6-DM1 conjugate (DM1 dose of 200 μg/kg, qd×5)administered intravenously. The second group received MY9-6-DM3conjugate (DM3 dose of 200 μg/kg, qd×5) administered intravenously. Thethird group received MY9-6-DM4 conjugate (DM4 dose of 200 μg/kg, qd×5)administered intravenously, while a fourth group of animals served ascontrols and received PBS using the same treatment schedule as in groups1-3.

The sizes of the tumors were measured twice weekly and the tumor volumeswere calculated with the formula: tumor volume=½(length×width×height).The weight of the animals was also measured twice per week. The resultsare shown in FIG. 9. The tumors in the control group of mice grewrapidly to a size of nearly 1600 mm³ in 21 days. Treatment withMY9-6-DM1 resulted in a tumor growth delay of about 5 days, whileconjugates made with the maytansinoids 4a and 4b of the presentinvention were significantly more efficacious prolonging the tumorgrowth delay to greater than 20 days.

Example 9 Preparation of a Cytotoxic Conjugate of huMy9-6 Antibody UsingMaytansinoid DM4 (4b)

A solution of huMy9-6 antibody at a concentration of 8 mg/mL wasincubated for 2 h with a 6.5 molar excess of SSNPB [sulfosuccinimidyl4-(5′-nitro-2′-pyridyldithio)butyrate] in 50 mM potassium phosphatebuffer, pH 6.5, containing 2 mM ethylenediaminetetraacetic acid (bufferA) with 5% ethanol. The modified antibody was purified by passagethrough a Sephadex G25 gel filtration column equilibrated in buffer Aand the concentration of the purified antibody was determinedspectrophotometrically using the extinction coefficient for the antibodyat 280 nm. The modified antibody was diluted to 4.9 mg/mL with buffer Aand incubated for 18 h at room temperature with 1.7-fold molar excess ofDM4, which was added to the reaction mixture as a stock solution indimethylacetamide (final concentration of dimethylacetamide was 3% v/v).The antibody-drug conjugate was purified by passage through a SephadexG25 column equilibrated in PBS, pH 6.5. The concentration of conjugatewas determined spectrophotometrically using the know extinctioncoefficients for antibody and DM4 (for the antibody, ε_(280 nm)=206,460M⁻¹ cm⁻¹, ε_(252 nm)=72,261 M⁻¹ cm⁻¹; for DM4, ε_(280 nm)=5,700 M⁻¹cm⁻¹, ε_(252 nM)=26,790 M⁻¹ cm⁻¹). The resulting antibody-drug conjugatecontained an average of 3.6 DM4 molecules per antibody molecule.Biochemical analysis demonstrated that the antibody remained greaterthan 94% monomeric following conjugation and had a binding affinitycomparable to the unmodified antibody as determined by flow cytometry.The amount of drug associated with the antibody that was not linkedcovalently (free drug) was determined by HPLC analysis and found to beless than 1% of the total linked drug.

Example 10 In Vitro Selectivity and Efficacy of huMy9-6-DM4 Conjugate

The cytotoxicity of huMy9-6-DM4 toward CD33 expressing cells (HL-60) andCD33-negative Namalwa cells was tested using a clonogenic assay, wherecell killing activity is determined by quantifying the number ofcolonies that can grow following treatment. huMy9-6-DM4 exhibits potentcell killing activity toward CD33-positive HL-60 human tumor cells invitro (FIG. 10). No significant toxicity toward CD33-negative humanNamalwa cells was observed, indicating that the CD33-dependentcytotoxicity was due to specific targeting by the anti-CD33 antibody,huMy9-6 of the conjugate.

Example 11 In Vivo Efficacy of huMy9-6-DM4 Conjugates Against HL60 HumanTumor Xenografts in SCID Mice

The efficacy of huMy9-6-DM4 in vivo was determined in SCID mice bearinghuman HL-60 tumor xenografts. HL-60 cells were injected subcutaneouslyand tumors were allowed to grow to an average size of 100 mm³.HuMy9-6-DM4 conjugate was delivered i.v. once a day for 5 days at thedose indicated in FIG. 11. Dosage is expressed as μg DM4 in theconjugate, which corresponds to an antibody dose of approximately 67 μgantibody per μg of DM4. Tumor volume was measured as an indication oftreatment efficacy and mouse body weight was monitored to indicatetoxicity due to treatment. huMy9-6-DM4 induces prolonged tumor growthdelay of human HL-60 cell xenografts at doses that cause little toxicity(FIG. 11). The efficacy of huMy9-6-DM4 was also compared with that ofhuMy9-6-DM1. Unexpectedly, it was found that huMy9-6-DM4 was moreeffective than huMy9-6-DM1. HuMy9-6-DM4 maintained the animals incomplete remission (CR) for nearly sixty days, whereas animals treatedwith huMy9-6-DM1 relapsed after about 20 days in CR.

Example 12 Preparation of a Cytotoxic Conjugate of huB4 Antibody UsingMaytansinoid DM4 (4b)

A solution of huB4 antibody at a concentration of 20 mg/mL was incubatedfor 1.5 h with an 8-fold molar excess of SSNPB [sulfosuccinimidyl4-(5′-nitro-2′-pyridyldithio)butyrate] in 50 mM potassium phosphatebuffer, pH 6.5 containing 2 mM ethylenediaminetetraacetic acid (bufferA) with 5% dimethylacetamide. The modified antibody was purified bypassage through a Sephadex G25 gel filtration column equilibrated inbuffer A and the concentration of the purified antibody was determinedspectrophotometrically using the extinction coefficient for the antibodyat 280 nm (199,560 M⁻¹ cm⁻¹). The modified antibody was diluted to 8mg/mL with buffer A and incubated for 3 h at ambient temperature with a1.7-fold molar excess of DM4, which was added to the reaction mixture asa stock solution in dimethylacetamide (final concentration ofdimethylacetamide was 3% v/v). The antibody-drug conjugate was purifiedby passage through a Sephadex G25 column and a Sephadex S300 column,both equilibrated in PBS buffer, pH 6.5. The concentration of conjugatewas determined spectrophotometrically using the know extinctioncoefficients for antibody (ε_(280 nm): 199,560 M⁻¹ cm⁻¹; ε_(252 nm):67,850 M⁻¹ cm⁻¹) and DM4 (ε_(280 nm)=5,700 M⁻¹ cm⁻¹, ε_(252 nM)=26,790M⁻¹ cm⁻¹). The resulting antibody-drug conjugate contained an average of4.0 DM4 molecules per antibody molecule. Biochemical analysisdemonstrated that the antibody remained greater than 98% monomericfollowing conjugation and had a binding affinity comparable to theunmodified antibody as determined by flow cytometry. The amount of drugassociated with the antibody that was not linked covalently (free drug)was determined by HPLC analysis and was approximately 2% of the totallinked drug.

Example 13 In Vitro Selectivity and Efficacy of huB4-DM4 Conjugate

The cytotoxicity of huB4-DM4 toward CD19-expressing cells (Ramos)compared to a CD19-negative cell line (Colo 205) was tested using anMTT-based assay, where cell killing activity is determined byquantifying the number of viable cells that remain following treatmentwith conjugate. Viable cell number is determined by spectrophotometricquantitation following incubation of the cells with the vital dye MTT.HuB4-DM4 exhibits potent cell killing activity toward CD19-positiveRamos human tumor cells in vitro (FIG. 12). No significant toxicitytoward CD19-negative cells was observed, indicating that theCD19-dependent cytotoxicity was due to specific targeting by theanti-CD19 antibody, huB4.

Example 14 In Vivo Efficacy of huB4-DM4 Conjugate Against Ramos HumanTumor Xenografts in SCID Mice

The efficacy of huB-DM4 in vivo was determined using SCID mice bearingestablished human Ramos tumor xenografts. Ramos cells were injectedsubcutaneously and tumors were allowed to grow to an average size of 100mm³. HuB4-DM4 conjugate was delivered i.v. as a single injection at thedoses indicated in FIG. 13 a. Dosage is expressed as μg DM4 in theconjugate, which corresponds to an antibody dose of approximately 44 μgantibody per μg of DM4. Tumor volume was measured as an indication oftreatment efficacy and mouse body weight was monitored to indicatetoxicity due to treatment. At doses above 50 μg/kg, HuB4-DM4 causescomplete regression of the tumors in all animals. Animals remain withoutmeasurable disease for about 35 days in the 100 mg/kg treatment group,and for more than 55 days in the two highest dose groups. Thesetreatments caused very little if any toxicity (FIG. 13 b) as judged bychanges in the body weight of the treated animals.

1-98. (canceled)
 99. A maytansinoid-cell-binding agent conjugate,wherein the maytansinoid is represented by formula 4₁:

wherein: Y₁ represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂S—,wherein: R₁ and R₂ are each independently linear alkyl or alkenyl havingfrom 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl havingfrom 3 to 10 carbon atoms, phenyl, phenyl substituted with at least onealkyl containing from 1-4 carbon atoms, or an alkoxy, halogen or nitro,or heterocyclic aromatic or heterocyclic radical, and in addition R₂ canbe H; R₃, R₄, R₅, R₆, R₇ and R₈ are each independently H, linear alkylor alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl oralkenyl having from 3 to 10 carbon atoms, phenyl, phenyl substitutedwith at least one alkyl containing from 1-4 carbon atoms, or an alkoxy,halogen or nitro, or heterocyclic aromatic or heterocyclic radical; l, mand n are each independently an integer of from 1 to 5, and in additionn can be 0, and wherein said heterocyclic aromatic radical or saidheterocyclic radical is a 3-10 membered ring containing one or twoheteroatoms selected from N, O or S, and the cell-binding agent isselected from the group consisting of a humanized or resurfaced antibodythat specifically binds to the CD33 antigen and comprises a heavy chainand a light chain, said heavy chain comprising three complementaritydetermining regions comprising HCCDR1, HCCDR2 and HCCDR3 of murineantibody MY9, and wherein said light chain comprises threecomplementarity determining regions comprising LCCDR1, LCCDR2 and LCCDR3of murine antibody My9; a humanized or resurfaced antibody thatspecifically binds to the CD19 antigen and comprises a heavy chain and alight chain, said heavy chain comprising three complementaritydetermining regions comprising HCCDR1, HCCDR2 and HCCDR3 of murineantibody B4, and wherein said light chain comprises threecomplementarity determining regions comprising LCCDR1, LCCDR2 and LCCDR3of murine antibody B4, and a humanized or resurfaced antibody thatspecifically binds to the CanAg antigen and comprises a heavy chain anda light chain, said heavy chain comprising three complementaritydetermining regions comprising HCCDR1, HCCDR2 and HCCDR3 of murineantibody C242, and wherein said light chain comprises threecomplementarity determining regions comprising LCCDR1, LCCDR2 and LCCDR3of murine antibody C242.
 100. The conjugate of claim 99, wherein R₁ andR₂ are methyl; R₅, R₆, R₇ and R₈ are each H; l and m are 1; and n is 0.101. The conjugate of claim 100, wherein the cell-binding agent is ahumanized or resurfaced antibody that specifically binds to the CD19antigen and comprises a heavy chain and a light chain, said heavy chaincomprising three complementarity determining regions comprising HCCDR1,HCCDR2 and HCCDR3 of murine antibody B4, and wherein said light chaincomprises three complementarity determining regions comprising LCCDR1,LCCDR2 and LCCDR3 of murine antibody B4.
 102. The conjugate of claim100, wherein the maytansinoid and the cell-binding agent are covalentlylinked via a cross-linker having a disulfide bond.
 103. The conjugate ofclaim 101, wherein the maytansinoid and the cell-binding agent arecovalently linked via a cross-linker having a disulfide bond.
 104. Theconjugate of claim 100, wherein the maytansinoid and the cell-bindingagent are cross-linked using N-succinimidyl-4-(2-pyridyldithio)butanoate(SPDB).
 105. The conjugate of claim 101, wherein the maytansinoid andthe cell-binding agent are cross-linked usingN-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB).
 106. The conjugateof claim 100, wherein an average of 1-10 maytansinoid molecules is boundper antibody.
 107. The conjugate of claim 101, wherein an average of1-10 maytansinoid molecules is bound per antibody.
 108. The conjugate ofclaim 106, wherein the conjugate is represented by the followingformula:

wherein w is 1-10.
 109. The conjugate of claim 107, wherein theconjugate is represented by the following formula:

wherein w is 1-10.
 110. A pharmaceutical composition comprising aneffective amount of the conjugate of claim 99 or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier,diluent or excipient.
 111. A pharmaceutical composition comprising aneffective amount of the conjugate of claim 100 or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier,diluent or excipient.
 112. A pharmaceutical composition comprising aneffective amount of the conjugate of claim 101 or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier,diluent or excipient.
 113. A pharmaceutical composition comprising aneffective amount of the conjugate of claim 108 or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier,diluent or excipient.
 114. A pharmaceutical composition comprising aneffective amount of the conjugate of claim 109 or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier,diluent or excipient.
 115. A method of making themaytansinoid-cell-binding agent conjugate of claim 99, said methodcomprising reacting a maytansinoid of formula 4

wherein: Y represents (CR₇R₈)_(l)(CR₅R₆)_(m)(CR₃R₄)_(n)CR₁R₂SZ, wherein:Z is H, SR or —COR wherein R is linear alkyl or alkenyl having from 1 to10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3-10carbon atoms, or simple aryl or aryl substituted with at least one alkylcontaining from 1-4 carbon atoms, or an alkoxy, halogen or nitro, orheterocyclic aromatic or heterocyclic radical, wherein said heterocyclicaromatic radical or said heterocyclic radical is a 3-10 membered ringcontaining one or two heteroatoms selected from N, O or S, with saidcell-binding agent, wherein said cell-binding agent comprises a reactivedithio group.
 116. The method of claim 115, wherein R₁ and R₂ aremethyl; R₃, R₄, R₅, and R₆ are each H; l and m are 1; n is 0 and Z is H.117. The method of claim 116, wherein the cell-binding agent is ahumanized or resurfaced antibody that specifically binds to the CD19antigen and comprises a heavy chain and a light chain, said heavy chaincomprising three complementarity determining regions comprising HCCDR1,HCCDR2 and HCCDR3 of murine antibody B4, and wherein said light chaincomprises three complementarity determining regions comprising LCCDR1,LCCDR2 and LCCDR3 of murine antibody B4.
 118. The method of claim 115,wherein the reactive dithio group is a substituted dithiopyridyl groupfrom N-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB).
 119. The methodof group 116, wherein the reactive dithio group is a substituteddithiopyridyl group from N-succinimidyl-4-(2-pyridyldithio)butanoate(SPDB).
 120. The method of group 117, wherein the reactive dithio groupis a substituted dithiopyridyl group fromN-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB).